Podcasts about BMS

We Like Shooting We Like Shooting - Ep 676 August 17, 2026 Presented by This episode of We Like Shooting is brought to you by: Foxtrot Mike (Code: WLSISLIFE) C&G Holsters (Code: WLSISLIFE) Gideon Optics (Code: WLSISLIFE) Midwest Industries (Code: WLSISLIFE) Blue Alpha Night Fision (Code: WLSISLIFE) Otis Technology (Code: WELIKESHOOTING15) Giveaways!! GAW   Text Dear WLS or Reviews +1 743 500 2171 Public   Show Titles   Gear Chat Note Montana Knife Company stoned goat ultrahttps://www.montanaknifecompany.com/products/stoned-goat-ultra EAA Corp. Girsan Witness2311 CMX XXX Discover the Witness2311 CMX XXX, a compact double stack 1911 with 16+1 capacity, a slim grip, firing pin block safety, and two-tone finish. The Girsan Witness2311 CMX XXX is a compact single-action 9mm pistol from EAA Corp. with 16+1 capacity using Check-Mate magazines. It features an RMSc-footprint optic-ready slide, 3.4-inch coned barrel, two-tone Cerakote finish, low-profile 3-dot sights, ambidextrous thumb safety, 4-slot Picatinny rail, and EAA limited lifetime warranty. Availability: Available for purchase via Add to Cart on eaacorp.com (no explicit stock, release date or additional retailers stated) Cost: $899 Special: Streamlined compact grip with aggressive texturing, low-profile magwell, and automatic firing pin block safety replacing traditional grip safety for 16+1 capacity without added bulk Odysee (Nick) SecondWatch FTN.6 Suppressor Pack Update: We received overwhelming feedback that people did not like the text. The intention was to save on what needed to be engraved. Since it is so unpopular, all text has been removed from the model… The FTN.6 Suppressor Pack is a downloadable set of 3D-printable files for DIY suppressors released by SecondWatch on August 15, 2026, via Odysee. It includes updated designs for rimfire, 5.56, and 300 BLK models that are described as the quietest FTN variants to date, matching or surpassing many commercial suppressors in head-to-head testing. The pack continues the FTN (Fuck The NFA) series focused on accessible, low-cost polymer printed silencers. Availability: Released August 15, 2026 on Odysee (@SecondWatch); downloadable files Special: FTN.6 Air is a very lightweight (~10.6 oz) and slim rifle suppressor using thread adapters; modular flash hider and compensator add-ons; FTN.6 Rimfire offers similar sound reduction to FTN.5 but in a smaller package Defiance Machine (Nick) Defiance Machine Deviant Comp Rifle Action Deviant COMP – The new standard for PRS competitors. The Deviant COMP refines our popular Deviant model into a purpose-built precision rifle action designed specifically for PRS competitors who demand speed, consistency, and reliability under pressure. Built with the features competitive shooters actually want, the Deviant COMP features an oversized bolt for fast cycling, an AW magazine cut compatible with both AW and AICS magazines, and guaranteed headspace for repeatable accuracy and hassle-free builds. This makes the Deviant COMP a competition-ready package that is ideal for PRS. Finished with nitride included at no additional cost, the Deviant COMP delivers premium performance at an exceptional value. Specifications Integral scope mount/rail. Integral recoil lug. Defiance swept legacy bolt design. Oversized competition bolt knob. Smooth chrome-moly bolt action with anti-bind design. Recessed bolt lugs, Mini-16 extractor, and plunger ejector. AW magazine cut. Trigger pins included. Nitride finish included. Why choose the Deviant COMP? PRS competition-ready feature set. Integral rail and recoil lug means more rigidity and reliability when it matters most. Receiver is made from once piece of pre-hardened aircraft-certified 416 stainless steel, allowing for tight manufacturing tolerances and increased performance. One-piece legacy bolt, machined to exacting tolerances required to cycle as smooth as possible. Swept bolt handle design to allow plenty of clearance with your rifle scope. Precision extraction system that significantly increases initial extraction and improves smooth bolt cycling. Need an extra bolt? Extra bolts are available when purchasing your action over the phone with our team for $495 each (includes extractor, ejector, and fire control assembly). The Deviant Comp is a purpose-built short-action bolt-action receiver from Defiance Machine, refined from the standard Deviant for PRS competitors. It is machined from a single piece of pre-hardened 416 stainless steel with an integral scope rail and recoil lug for rigidity and guaranteed headspace. It features an oversized competition bolt knob, swept bolt handle, anti-bind design, AW/AICS magazine compatibility, nitride finish, and a smooth chrome-moly bolt with recessed lugs, Mini-16 extractor, and plunger ejector. Availability: Available through retailers including Red Hawk Rifles (add-to-cart with options) and Altus Shooting (currently out of stock for specific variants like RH/308) Cost: $1,495.00 Special: PRS-optimized with oversized bolt for fast cycling, AW magazine cut compatible with AW and AICS, integral rail/lug for rigidity, and included nitride finish at no extra cost 270 Videos Removed from YouTube for FRN and WLS in Recent Days 270 videos removed from youtube for FRN and WLS in the last several days. Supplementary Research: Firearms Radio Network (FRN) produces multiple gun-related podcasts including the long-running We Like Shooting (WLS) show, which features discussions on firearms, gear, training, and current events. The claim states that 270 videos associated with these channels were removed from YouTube over several days in 2026. YouTube's enforcement actions in 2026 have included widespread removals tied to updated policies on AI-generated content, community guidelines, and monetization standards, with millions of videos and channels affected platform-wide. Gun Fights Play the best Price Is Right-style GunBroker game on the internet. Gun Fights Live DisplayFollow the game, prices, and reveals as they happen.Open the live display BangRank A live cast ranking segment for anything and everything in the gun world, powered by questionable certainty, strong opinions, and audience voting. BangRank Live VotingScan or open the link to rank along with the show.https://welikeshooting.com/rank   WLS is Lifestyle GunCAD Index 2011 OPTICS MAXXING by Foaps Files Designed specifically for the Nightalliance 2011 Maxxing frames. There are two styles to choose from and six different optic mounting patterns. Each … This is a 3D model release on GunCAD Index containing STEP and STL files for optic mounts designed specifically for Nightalliance 2011 Maxxing frames. It offers two styles, six optic mounting patterns (including ACRO, Docter-Noblex, Pic Rail, RMR, RMSc, T1-T2), Gas Pedal and Non-Gas Pedal variants, plus length options for Full, Commander, and Short frames. The page serves as an indexed preview only; actual files must be acquired from the original source. Why it Matters: Enables precise red-dot integration on custom 2011 pistols in the growing 3D2A community, allowing shooters to upgrade iron-sight platforms with modern optics without factory limitations. The Vibe: Clean, modular CAD aesthetic with purposeful engineering details—gas pedal extensions, multi-pattern plates, and frame-specific lengths that emphasize performance-oriented customization over factory aesthetics. Hot Take: In the 2011 maxxing scene, bolting a quality optic directly to a printed or custom frame is now the baseline, not an afterthought. GunCAD Index Freedomware Sedco SP22:8 SPEDBRO SP22 Printable 22LR Pistol Don't like the standard Jennings J22? Well here's his neglected brother, the Sedco SP22. A knockoff of the already trash J22. NOT FOR DISTRIBUTION O… The SPEDBRO SP22 is a 3D-printable knockoff of the Sedco SP22 / Jennings J22 design by FreedomWare. It is a rimfire 22 Long Rifle handgun classified as a printed firearm using DIY barrel, bolt, and fire control with no firearm parts required. The release includes multiple STL files, reference images, a drill key, and README; total size 2.5 MiB; explicitly not for distribution on DEFCAD; tagged for FOSSCAD and 3D2A. Why it Matters: Provides a fully printable 22LR plinking handgun design that requires no commercial firearm parts, enabling DIY production of a simple rimfire pistol using consumer 3D printing and basic tools. The Vibe: Utilitarian homemade aesthetic with blocky printed polymer grips and frame, exposed metal DIY barrel/bolt, and reference photos showing side-by-side comparison to a Bryco 22; raw FOSSCAD open-source vibe with technical STL and drill-key files. Hot Take: A knockoff of the already trash J22 – the neglected brother Sedco SP22 now lives on as a fully printable FreedomWare project for the 3D2A community. Guncadindex Tritschi 60 Seconds Timer for Shooting Range A self-built horizontal hourglass-style mechanical countdown timer using a stepper motor, GT2 belt, Nema17, Arduino Nano, and 3D-printed parts. It provides a large 160 cm x 90 mm visual window that transitions from white to red over exactly 60 seconds for timing K20-K23 handgun events in DSU disciplines, with startup red LED/beeper sequence, green LED indicator, optional beeper, and planned light-sensor start. Powered by 3S Li-Ion with BMS; designed in TinkerCad and printed on Prusa MK4/Sovol SV08. Why it Matters: Best Use Case: Competition (K20-K23 handgun events in German DSU shooting sports; helps pace 18 shots in 60 seconds without digital distractions or crowd noise) Hot Take: Quick Pro/Con: Pro – Large peripheral-vision mechanical analog display improves focus and timing accuracy; Con – Self-built (requires 3D printing,...

A control valve can look right on paper and still create control problems in the field. For building automation professionals, valve sizing directly affects what you see at the controller. Unstable loops, limited valve travel, poor response, and persistent comfort complaints may appear to be programming or tuning issues when the real problem started with valve selection. In Episode 557 of the Smart Buildings Academy Podcast, Valve Sizing 101, you'll learn how to think about control valves as precision control elements rather than simple devices for passing water. Understanding what happens between valve sizing, pressure drop, authority, and the coil can help you recognize when a hydronic problem needs more than another round of loop tuning. Topics Covered • Why valve sizing matters to BMS technicians and controls professionals • How valve authority affects modulation and control stability • What oversizing can do to valve performance and usable range • Why valve characteristics matter for heating and cooling coils • Where cavitation and flashing enter the valve sizing conversation If you work with hydronic systems, AHUs, terminal units, or control loops, this episode will help you connect what you see in the BMS to what is happening at the valve.

It's ev.news Briefly for Tuesday 04 August 2026, only today's headlines and just the facts in just 4 minutes if you haven't got time for the full show.Patreon supporters fund this show, get the episodes ad free, as soon as they're ready and are part of the ev.news Community. You can be like them by clicking here: https://www.patreon.com/evnewsEVS TAKE THE LEAD IN IRELAND'S NEW-CAR MARKET AS JULY HITS NEW RECORDBattery electric vehicles have become Ireland's top new-car fuel type, with July setting a record of 9,682 BEV registrations, up 97.67% year on year, taking the seven-month total to 29,840 units, a 61.06% rise on 2025. EVs held 26.1% of the market over that period, ahead of petrol-electric hybrids at 24.6%, petrol at 20.4%, PHEVs at 14.5% and diesel at 12.5%, with Nevo's Derek Reilly crediting lower running costs, newer technology and models priced between €20,000 and €30,000 for reaching the tipping point.VOLVO EX50 SET FOR US IN 2027Volvo will bring the EX50 compact electric crossover to US and Canadian showrooms in autumn 2027 at a price in the high $40,000s, replacing the EX40 as its entry-level US EV and filling a gap left when the EX30 and EX30 Cross Country exit after the 2026 model year. Production starts in spring 2027 at Volvo's $1.3 billion, 250,000-unit Kosice plant in Slovakia, using the SPA3 modular platform with an 800-volt system for faster charging, better efficiency and flexible battery and motor combinations.HYUNDAI AND KIA TOP 100,000 EUROPE EVSHyundai and Kia sold a combined 131,032 EVs in Europe in H1 2026, their first half-year above 100,000, putting them on course to beat 2025's full-year 183,912, as European BEV registrations rose 33.7% to over 1.24 million and took roughly 22% of the market. The Kia EV3 led with 27,121 units from around €36,000, while cheaper models filled out the range: the Hyundai Inster sold 16,594 units, the Kia EV2 launched in Germany in March at €26,600, and the EV4 added 14,502 units during its ramp-up.FRENCH BEV SHARE HITS 35% IN JULYBattery-electric cars took 35% of French new-car registrations in July 2026, with the PFA recording 44,378 BEVs from a market of 126,808 units that grew 9% year on year, roughly double the share of two years earlier. The rise coincided with Round 3 of France's social leasing scheme, reopened on July 16, which covers 29% of purchase price up to €6,500, rising to €9,000 for EEA-built vehicles and batteries plus €500 for an EEA motor, caps payments at €200 a month with no deposit, and has drawn offers such as the Citroën ë-C3 from €94 a month and Renault Twingo from €130.NORWAY HITS 97.6% EV SHARE IN JULYNorway registered 9,609 new passenger cars in July, up 0.5% year on year, of which 9,379 were battery-electric, a 97.6% share up from 96.9% in June, while Østfold reached 99.6% with 672 of 675 registrations. Used-market data followed suit, with private ownership transfers of used EVs up 8% in July against falls of 5.7% for diesel and 6.7% for petrol, and year-to-date used EV transfers up 43.2% to 103,892, now ahead of diesel overall.ALSO STARTS TM-B DELIVERIES AFTER DELAYAlso will deliver its first Launch Edition TM-B electric bikes this week through mid-September, ending a delay caused by an industry-wide surge in demand for raw materials and electronic components that left the bike short of key parts and stalled its manufacturing ramp-up. The TM-B uses a pedal-by-wire system in which pedalling spins a generator that communicates with the motor, with no mechanical link to the wheel, alongside a slick interface, over-the-air updates and a modular frame that accepts different seats and cargo racks.NISSAN SHOWS INTERSTAR-E ELECTRIC CAMPERVANNissan and German converter Eifelland will debut the Interstar-e Relax electric campervan at the Caravan Salon in Düsseldorf this month, using a Truma Eezy parking heater powered by vehicle-to-load from the 87 kWh traction battery, removing the need for a campsite hookup, diesel generator or engine idling. The donor van is rated at up to 255 miles (410 km) WLTP unladen, though the conversion's added weight will cut that materially, with 130 kW DC and 22 kW AC charging, a fixed bed, 90-litre fridge, induction hob, sink, wood trim and portable toilet, priced at €89,900 (about $102,000).CHUNG CHECKS IONIQ 3 TURKEY LAUNCHHyundai Motor Group Executive Chair Chung Eui-sun toured the group's Izmit plant near Istanbul on July 30 to check production readiness and quality control ahead of Ioniq 3 mass production in mid-August, also visiting Hyundai Mobis's Battery System Assembly plant and urging staff to make the car one of Europe's safest. The Ioniq 3 is Hyundai's first subcompact BEV built for Europe and the first EV made at Izmit, which has built combustion compacts since 1997, and it will roll out across Europe in H2 2026 as the first Hyundai there with the next-generation Pleos Connect infotainment system.FARIZON CUTS AUSTRALIAN SV VAN PRICESFarizon has cut prices by up to A$8,500 (US$5,570) across its SV electric van range in Australia, extending EV price competition into the light commercial segment, with revised pricing now starting at A$62,990 (US$41,260) before on-road costs for the SWB. The mid-size SV, with roughly 1t to 1.2t of payload, previously came in SWB low roof, LWB low roof and LWB high roof forms with an 83 kWh LFP battery, and has been joined by an SLWB high roof variant using a 106 kWh NMC pack.MASSACHUSETTS TARGETS EVS FOR GRID PAYMENTSMassachusetts plans to add electric cars to its virtual power plant under the next phase of ConnectedSolutions, paying owners to export power at peak times and extending vehicle-to-grid from school buses and commercial fleets into private driveways. The state's 150,000-plus EVs represent a notional 11.25GWh of storage at 75kWh each, though depth-of-discharge limits, charger power and everyday driving needs reduce that considerably; eligible models at launch are the Ford F-150 Lightning, Nissan Leaf, Kia EV9, Polestar 3 and Volvo EX90, paying $275 per average kilowatt delivered during summer events, or roughly $1,375 to $2,750 a season.QUEENSLAND E-BIKE CRACKDOWN NETS 991 TICKETSQueensland police issued 991 traffic infringement notices to e-bike riders in the first month of Operation Yankee Surety, which began on 1 July, averaging 32 a day, alongside 249 impounded illegal machines and 24 people charged with drink-riding. The crackdown rests on new laws allowing roadside seizure of non-compliant devices and breath-testing, with devices capable of exceeding 25km/h (15.5mph) banned outright and motors required to be restricted to that limit.ROMANIAN POWER CRUNCH STOPS FORD AND DACIAFord and Dacia have halted production at their Romanian factories through Aug. 19 after severe electricity shortages hit the country. Ford has suspended production of the Puma Gen E in Craiova, 230 km (134 miles) west of Bucharest.TESLA MODEL 3 POWERS HANDMADE MINI JETBOATYouTuber Tyler Fever spent three years stripping a 2021 Tesla Model 3 and fitting its drivetrain into a handbuilt aluminium mini jetboat hull, machining a custom output shaft to bypass the 9:1 reduction and couple the rotor directly to the jet pump, since the motor's roughly 18,000 rpm gave around 2,000 rpm against the 6,000–8,000 rpm impellers need. He used a standard-range pack for its smaller footprint, mounting four modules of about 150 lbs (68 kg) each vertically in laser-cut enclosures, and had to replace the factory BMS and motor controller with an Orion BMS and third-party inverter after they failed to communicate, with the series covering a successful lake run and later testing in Nashville.

This week we listened to America's favorite celebration of backless underpants, Thong Song by Sisqo, released Feb.15, 2000. This guy loves thongs and we have questions. Spoiler alert this episode features very few thongs despite the song title.  Also in this prepisode music news of the weird, listener emails and we announce next week's album.  In this episode we discuss Tim's new obsession with Looksmaxxing, when nicknames go wrong, the appropriate amount of fudge per serving, the invention of the thong, why no one should be friends with Chris Brown, Tim shouting about BMs in public, destroying pool inflatables, why everyone is in Saudi Arabia these days, practical jokes with Anthony Hopkins, and so much more!  Hatepod.com | TW: @AlbumHatePod | IG: @hatePod | hatePodMail@gmail.com Episode Outline: Quick update on the goings on at the world headquarters Discuss our history with the song/band Song discussion - lyrics and music Music Video How the song did worldwide Amazon reviews Listener email (just 2) Music news of the weird Announce next week's album

US equity futures are trading higher, with the S&P up around 0.6%. Bonds are firmer, with the US 10-year yield down 2 bps at 4.7% and the Bund down 5 bps at 3.2%. The dollar is mixed, firmer against the euro, sterling, and the Aussie, but under pressure versus the yen following FX intervention. In commodities, oil is notably weaker, with WTI crude down 6.5% below $80 a barrel, while gold is trading firmer and industrial metals are mostly lower. Bitcoin is also lower. Market sentiment is benefiting from news that President Trump called off planned strikes against Iran to allow room for negotiations over Strait of Hormuz. Trump said talks would begin Monday and posted parameters of deal have been agreed to. Iran echoed by noting an agreement on Strait of Hormuz close. Companied mentioned: AstraZeneca, BMS, Shell Plc, Blackstone

Lovaglio non si dà per vinto, Mps valuta di lanciare un'offerta su Bpm; Petrolio a picco, Trump annuncia colloqui con l'Iran; Yen in netto rialzo dopo l'intervento congiunto di Usa e Giappone; Domani SpaceX al test, prima trimestrale da quotata; Astrazeneca e BMS valutano di unire le forze, nascerebbe il quarto gruppo pharma al mondo Puntata a cura di Elisa Piazza - Class CNBC Learn more about your ad choices. Visit megaphone.fm/adchoices

Adam Haman returns, this time helping Bob critique Carl Jung's "Answer to Job."Mentioned in the Episode and Other Links of Interest:The YouTube version of this episode.Carl Jung's "Answer to Job."This episode's featured company, Jackery.RC Sproul on Job.BMS ep. 420 unpacking Darryl Cooper's religious heresies.The HamanNature substack.Help support the Bob Murphy Show.

We Like Shooting We Like Shooting - Ep 672 July 20, 2026 Presented by This episode of We Like Shooting is brought to you by: Foxtrot Mike (Code: WLSISLIFE) C&G Holsters (Code: WLSISLIFE) Midwest Industries (Code: WLSISLIFE) Blue Alpha Night Fision (Code: WLSISLIFE) Bowers Group (Code: WLS) Second Call Defense Giveaways!! GAW   Text Dear WLS or Reviews +1 743 500 2171 Public   Show Titles   GOA GOALS Aug 1-2 in Iowa. https://goals.goa.org/ Gear Chat Instagram (Savage) Da6kzNIulLc 36 likes, 17 comments – savage1r on July 17, 2026: "When you absolutely, positively, obsessively do not want to smell the smoke in your house during fire season. #airpurifier #air #fans #filter". https://www.instagram.com/reel/Da6kzNIulLc/?utm_source=ig_web_copy_link&igsh=MzRlODBiNWFlZA== Note Tacticaltoggle.com thefirearmblog.com Springfield Armory Echelon Alpha An Echelon, but More Affordable?Springfield Armory Unveils the NEW Echelon AlphaThe Springfield Armory Echelon is the pistol of choice for a lot of shooters because of its wide package of accoutrements and modern features.The only gripe that some shooters raise is that the more tricked out variations might be too expensive for their budget. Springfield Armory announced the Echelon Alpha, a 9mm striker-fired pistol built on the Central Operating Group with a serialized stainless steel chassis. It features a recontoured billet machined slide with Melonite finish, 4″ hammer-forged barrel, optics-ready Variable Interface System, and ships with one stainless steel magazine. The design emphasizes purpose-driven ergonomics with a small grip module and reduced overall dimensions compared to the standard Echelon. Availability: Unveiled July 14, 2026; three initial models (standard, low-capacity, CA-compliant) offered directly via Springfield Armory Cost: $599 (standard and low-capacity); $649 (CA-compliant) Special: Variable Interface System for direct optic mounting combined with recontoured slide, captive recoil system, and single stainless steel magazine shipment EnVeeGee 2.0 DIY Night Vision 1078126 Enveegee 2 0 Diy Night Vision Download this free 3D print file designed by horizonalt.  Please notify me if anything is missing.The EnVeeGee is a digital-only refinement of the PVS-69 created by VonScherfArms. Using the technology available, a more purpose-built version of Vaughn's “Alpha” was designed and built to use only Amazon, Ebay, and Aliexpress hardware. No custom electronics were used to keep this build as accessible as possible. Odysee MMMIIT V1:7 Presenting the MMMIIT, or better known as the Monolithic Monocular Mx9644 Image Intensifier Tube Note Best can for my ps-90? Bullet Points Guncadindex Tritschi 60 Seconds Timer for Shooting Range A self-built horizontal hourglass-style mechanical countdown timer using a stepper motor, GT2 belt, Nema17, Arduino Nano, and 3D-printed parts. It provides a large 160 cm x 90 mm visual window that transitions from white to red over exactly 60 seconds for timing K20-K23 handgun events in DSU disciplines, with startup red LED/beeper sequence, green LED indicator, optional beeper, and planned light-sensor start. Powered by 3S Li-Ion with BMS; designed in TinkerCad and printed on Prusa MK4/Sovol SV08. Availability: Best Use Case: Competition (K20-K23 handgun events in German DSU shooting sports; helps pace 18 shots in 60 seconds without digital distractions or crowd noise) Special: Quick Pro/Con: Pro – Large peripheral-vision mechanical analog display improves focus and timing accuracy; Con – Self-built (requires 3D printing, electronics assembly, partial BOM only; no pre-built unit or price listed) Thefirearmblog 1791 Industries LiteRaider MMC Receivers 1791 Industries introduces LiteRaider MMC (Metal Matrix Composite) AR-15/M4 receivers made from a composite of pure metals and ceramic nanoparticles. They achieve 33% weight reduction versus standard aluminum while matching the strength of 7075-T6 aluminum, with Mil-Spec tolerances, anodized or Cerakoted finishes in Black or FDE. A matching lightweight accessory ecosystem including handguards is also offered. Availability: Military, law enforcement duty use and civilian lightweight fighting rifles (range, competition, hunting, EDC) Cost: Stripped upper 4.8 oz, stripped lower 6.2 oz (combined ~3.2 oz / 91 g reduction vs aluminum); compatible with AR-15/M4 platforms and MMC accessory line Special: Pro: 33% lighter with equivalent strength and durability; Con: Long-term recoil/vibration performance untested (monitor zero retention and group sizes) Guncadindex GRIP DEEZ (Printable AK Grip Nuts) by Haymarket Customs Printable AKM grip nut designed for fastening a pistol grip to the receiver. Prints without supports in under 30 minutes using PA6-GF/CF at 100% infill for less than $1 in materials. Requires 1x M6 jam/lock nut and 1x M6 screw (length varies by grip). Availability: Best Use Case: AKM rifle pistol grip installation (home-printed accessory) Recoilweb Kimber Warrior 1911 Optimized for Duty Use The article details the optimization of a used Kimber Warrior .45 ACP 1911, a commercial homage to the MCSOCOM Det 1 ICQBP sidearm. Upgrades include a Wolff Gunsprings 18.5 lb variable recoil spring, Nighthawk Custom one-piece magwell with lanyard loop, Nighthawk drop-in trigger pack (3.75-4 lb pull), 10-8 Performance flat trigger shoe, and VZ Simonich Gunner grips. The result is a reliable, enhanced single-stack 5-inch 1911 for duty/LE or armed citizen carry at a total cost of approximately $1,500. Availability: Duty use (LE, armed citizen, bedside/survival carry); reliable duty holster sidearm and last-resort pistol, homage to MCSOCOM ICQBP Cost: 5-inch barrel, single-stack narrow frame, 7-round capacity; compatible with duty holsters; weight not numerically stated (stock ~2 lbs implied) Special: Pro: Reduced recoil, crisp 3.75-4 lb trigger with short reset, faster reloads, solid grip, cost-effective reliability. Con: Requires gunsmith fitting for trigger shoe and possible safety mods; not fully plug-and-play Inside Safariland Top 7 Common Sense Ar 15 Upgrades https://pew.report/c/A4ksrC Thefirearmblog Colt Optics LP5X-P LE-Only Multi-Emitter Aiming Laser The Colt Optics LP5X-P, developed in partnership with Brolis Defence, is a NATO-standardized, weapon-mounted aiming laser restricted to law enforcement and military use. It integrates four co-aligned emitters in a compact polymer housing: a 26 mW visible green pointer, IR pointer, electronically adjustable IR illuminator, and VCSEL IR flood illuminator, all zeroing to the same point with minimal bore offset. Powered by a single CR123A battery, it features an IP68 seal, integral flip-up backup iron sight, gloved-hand controls, and MIL-STD-1913/STANAG 4694 rail compatibility, indicating a trend toward multi-spectrum, all-in-one aiming devices for tactical operators. Availability: Best Use Case: Law enforcement and military operations (daylight visible green pointer, night vision IR pointer/illuminator/flood) Cost: Size/Weight/Compatibility: 185 grams with single CR123A battery; mounts to MIL-STD-1913 or STANAG 4694 Picatinny rails; operates -32°C to +71°C; IP68 sealed Special: Quick Pro/Con: Pro – Four co-aligned emitters (visible green 26mW, IR pointer, adjustable IR illuminator, VCSEL flood) in one NATO-fielded unit with minimal POI offset and backup iron sight; Con – Restricted to LE/military sales only (approx. $2800 MSRP noted in comments), high cost may not justify for civilian multi-emitter use over simpler setups Guncadindex BLAPR 47:3 https://pew.report/c/VJnOjT Pew Report Pew Report Adds Guncad Index To Make 3d Printed Firearms More Approachable https://pew.report/c/np1wkP Note Historical documentaries on Netflix, Thomas Jefferson, Abraham Lincoln, Lincoln, Washington, Theodore Roosevelt, Grant, FDR, sitting bull, Thefirearmblog STINC o”ST”-14 Groza Kit The STINC o”ST”-14 Groza Kit is a drop-in bullpup conversion for PSA Krink (AK-74U pattern) pistols that approximates the Russian OTs-14 Groza. It includes an iconic carry handle with adjustable rear sight (notch/post or peep aperture for 100 and 200 yards) and a forward grip module containing the trigger and trigger guard. The kit uses all-metal construction with black phosphate finish and simplified machining for dimensional accuracy; compatible with 300 BLK, 7.62×39, and 5.56 Krink variants (fitting may be required on other AK platforms). No weight, dimensions, or price are stated. Availability: Range/competition/practical shooting conversion of short AK pistol to bullpup configuration Cost: Drop-in kit for PSA Krink variants (300 BLK, 7.62×39, 5.56); all-metal black phosphate; carry handle with adjustable rear sight (100/200 yd); forward grip with integrated trigger; no weight or OAL stated Special: Pro: Dimensionally accurate Groza look on affordable Krink platform; Con: Potential fitting on non-Krink AKs, forward grip may expose hand to heat/blast (per article comments) Soldiersystems Hrt Tactical Gear Releases The Hrt Holster Adapter A Semi Flexible Mounting Platform That Moves With You Not Hinders You https://pew.report/c/6Um14L Outdoorhub FALCO Holsters Minimalist Leather EDC Tray (O206) FALCO Holsters expands its concealed-carry ecosystem with a handcrafted leather EDC tray designed for organized storage of wallet, keys, headphones, and pocket items on a nightstand or entryway. Made from premium full-grain Italian leather with hand-painted edges and reinforced stitching in the same Slovakian workshop as their holsters....

BMS Summer Fling Vol. 1  In this segment of BMS we celebrate summer and all things hot with delight. After months of cold and unstable weather, this is a time for the BBQ and good music with good friends. It's time to look forward to the weeks and months ahead and enjoy the summers of the past.   I invite you to take this journey with BMS and snap open a ‘cold one' and soak up the sun like you used to do, because before you know it - it's gone.  This episode features Sly and the Family Stone, Bill Withers, Raydio, the Isley Brothers, and many more.  PLAYLIST   Summertime/ DJ Jazzy Jeff & the Fresh Prince  Hot Fun in the Summertime/ Sly & The Family Stone  Make It Hot/Teena Marie  Let The Sun In/ Atlantic Starr  Lovely Day/ Bill Withers  Everybody/ Roy Ayers  Hot Stuff/ Raydio  Summer fling/ The O'Jays  Too Hot/ Kool & the Gang  Sunshine/ Alexander O'Neal  Summer Love/ Rick James  Sunshine (Album Version)/ Floetry  The Isley Brothers/ Summer Breeze  Picnic in The Park/ MFSB 

On the 69th episode of Enterprise AI Innovators, hosts Evan Reiser (CEO and co-founder, Abnormal AI) and Saam Motamedi (General Partner, Greylock Partners) are joined by Greg Meyers, Chief Digital and Technology Officer at Bristol Myers Squibb. Bristol Myers Squibb is one of the top ten pharmaceutical companies, with about 30,000 employees and roughly 45 billion dollars in annual revenue, making specialty medicines in oncology, immunology, and neurology. Greg shares how BMS puts commercially scalable AI products in front of doctors, why a science company had to start thinking like a data company, and how a small-team accelerator de-risks ambitious AI bets in a highly regulated industry.Quick Hits from Greg:On thinking like a data company: "to models, negative results matter as much as positive results."On running small experimental teams: "making them too small to fail in a public or embarrassing way was really important."On what really gates AI adoption: "psychology and sociology trump technology every time."Like what you hear? Leave us a review and subscribe to the show on Apple, Spotify, and YouTube.Enterprise AI Innovators is a show where top technology executives share specific ways AI changes how work gets done in the enterprise.Find more great insights from technology leaders and enterprise software experts at https://www.enterprisesoftware.blog/Enterprise AI Innovators is produced by Abnormal Studios.

Last week, the government ordered Apple and Google to pull at least three battery management system or BMS apps that were being used to switch off e-rickshaws mid-road. If you've been on Instagram, you've seen the videos. A prankster opens the app, taps a switch, and a passing e-rickshaw just dies.It works because the cheap lithium batteries these vehicles run on often ship from China with their Bluetooth wide open, no password at all. The flaw was documented publicly years ago and nothing happened until it went viral. The batteries are still exposed. In this episode, host Snigdha Sharma asks what really governs safety in India's informal economy.Tune in.*We want to get to know you a little better. Tell us what you think about Daybreak here.Daybreak is produced from the newsroom of The Ken, India's first subscriber-only business news platform. Subscribe for more exclusive, deeply-reported, and analytical business stories.

In May 2026, our co-host Laurent Segalen had the privilege of chairing a high-profile panel hosted by SolarPower Europe at its annual Solar Power Summit in Brussels, one of the leading gatherings for the European solar and energy storage sectors.  In this episode, we bring you highlights from the hour-long conversation, featuring two distinguished industry leaders: Fredrik Andrén Sandberg from RWE and Hanna Kunzmann from EQT. Between them, their organisations oversee more than 10 GW of battery storage projects either in operation or under development, offering a unique perspective on the realities of financing and scaling storage assets.  The discussion addressed one of the most important questions facing the energy transition today: the bankability of battery storage investments. As battery deployment accelerates across Europe and beyond, investors, developers, and policymakers are increasingly focused on understanding the risks and opportunities that will determine the sector's long-term attractiveness.  The conversation examines battery bankability through four interconnected dimensions. First, technology risk: are batteries still exposed to meaningful technological uncertainty, or have the key challenges shifted towards commercial execution? Second, commercial risk: how should investors evaluate revenue models, merchant exposure, and the growing role of hybridisation strategies? Third, regulatory risk: what policy and market-design uncertainties could affect future returns, from evolving capacity mechanisms to unexpected rule changes? Finally, digital risk: how critical are cybersecurity, battery management systems (BMS), and energy management systems (EMS) in safeguarding performance and protecting asset value over the long term?  The session attracted a packed audience in Brussels and has since been widely praised for the quality, depth, and practical insights of the discussion. Whether you are an investor, developer, policymaker, or simply interested in the future of energy storage, this episode offers a valuable window into how some of the industry's leading players assess risk and opportunity in one of the fastest-growing sectors of the energy transition.

Bob recently appeared on the "Human Reaction" podcast, where host David Rand asked him various questions concerning the economics of AI. Although frequent BMS listeners will have heard these themes before, there is new material in this discussion.Mentioned in the Episode and Other Links of Interest:The YouTube version of this episode.The Human Reaction YT channel.This episode's sponsor, the free Plan-B guide from ExPatMoney.Help support the Bob Murphy Show.

Adam Haman returns to further discuss US monetary and economic history, with an emphasis on understanding the designs of the "American System" (propounded by Hamilton and later Clay).Mentioned in the Episode and Other Links of Interest:The YouTube version of this episode.The previous BMS ep. 507 on this topic. The Phoenician League archives.This episode's sponsor, the free Plan-B guide from ExPatMoney.Bob's Understanding Money Mechanics. Bob's aggressive plan for US fiscal reform. Bob's case for Texas secession.The HamanNature substack.Help support the Bob Murphy Show.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/the-evolving-role-of-antibody-drug-conjugates-in-metastatic-triple-negative-breast-cancer-10800SummaryThis CME/CE-certified podcast will provide multidisciplinary clinicians with an evidence-based update on the evolving role of TROP2-directed antibody-drug conjugates (ADCs) in the frontline treatment of metastatic triple-negative breast cancer. A medical and an ocular oncology specialist review the latest efficacy and safety data from pivotal clinical trials evaluating ADCs, their integration into contemporary treatment algorithms, and guideline recommendations based on PD-L1 status, BRCA mutation status, and immunotherapy eligibility. Learners will explore key factors influencing treatment selection, compare the benefits and limitations of more established therapeutic options, and examine practical strategies for preventing, recognizing, and managing ADC-associated toxicities. Special emphasis will be placed on multidisciplinary approaches to the management of ocular adverse events and other clinically significant toxicities to optimize patient outcomes and support safe implementation of these therapies in clinical practice.Learning ObjectivesEvaluate the current and emerging clinical evidence surrounding the use of trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugates (ADCs) in the first-line treatment of metastatic triple-negative breast cancer (TNBC)Integrate TROP2-directed ADCs into frontline treatment regimens for metastatic TNBC based on the latest clinical evidence, guidelines, and patient- and tumor-specific factorsApply multidisciplinary and patient-centric strategies for the prevention, recognition, and management of toxicities associated with the use of TROP2-directed ADCs in patients with metastatic TNBCThis activity is accredited for CME/CE CreditThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.50 contact hours (which includes 0.50 hours of pharmacology). For additional information about the accreditation of this program, please contact NACE at info@naceonline.com.Faculty and Moderator Aditya Bardia, MDProgram Director, Breast Medical Oncology, UCLAProfessor of Medicine, UCLALos Angeles, CADr. Bardia has disclosed the following financial relationships:Consultant: Alyssum, AstraZeneca/Daiichi, BMS, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer, VyomeAdvisor/Advisory Board: Alyssum, AstraZeneca/Daiichi, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer, VyomeContracted Research: AstraZeneca/Daiichi, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, PfizerStock options: Vyome (immuno-inflammatory and rare diseases)All of his consultant, advisor/advisory board, and contracted research disclosures are related to cancer.Maura Di Nicola, MDAssistant Professor of OphthalmologyBascom Palmer Eye InstituteMedical Director of Imaging and EchographyBascom Palmer Eye InstituteMiami, FLDr. Di Nicola has disclosed the following financial relationships:Consultant: AbbVie (ophthalmology), SpringWorks Therapeutics (oncology)Advisor/Advisory Board: AbbVie (ophthalmology)Research Grant: Castle Biosciences (ocular oncology)Please review additional planner disclosures here.Disclosure of Commercial SupportThis educational activity is supported by a medical education grant from AstraZeneca Pharmaceuticals and a medical education grant from Daiichi Sankyo, Inc.Please visit  http://naceonline.com to engage in more live and on demand CME/CE content.

Hour 4 of June 8, 2026 Jacob Townsend talks with Deb Williams, of Autoweek.com, about Denny Hamlin's second straight victory at Michigan, his 63rd career win, Carson Hocevar, Chase Elliott/Christopher Bell crash, Ned Jarrett passing, and more. Then, Jacob is joined by Brandon Cross, of Bristol Motor Speedway, to promote Super Grip NHRA Thunder Valley Nationals this weekend at BMS. Also, Jacob talks about Denny Hamlin's victory and Carson Hocevar's aggressiveness. See omnystudio.com/listener for privacy information.

Jacob Townsend is joined by Brandon Cross, of Bristol Motor Speedway, to promote Super Grip NHRA Thunder Valley Nationals this weekend at BMS.See omnystudio.com/listener for privacy information.

Adam Haman returns to help Bob offer praise and criticism for Jeremy Kauffman's recent speech at the Libertarian Party's national convention, as well as his appearance on the Tom Woods Show.Mentioned in the Episode and Other Links of Interest:The YouTube version of this episode.Jeremy Kauffman's appearance on the Tom Woods Show. His address to the LP national convention.Jeremy's interview on BMS ep. 368.This episode's sponsor, the free Plan-B guide from ExPatMoney.The "Universal Principles of Liberty."The HamanNature substack.Help support the Bob Murphy Show.

At the American Society of Clinical Oncology (ASCO) annual meeting in Chicago this past weekend, packed plenary sessions from Revolution Medicines and Summit Therapeutics' Chinese partner Akeso stole the show. For RevMed, analysts anticipate a potential approval in pancreatic cancer as early as this year, while Summit still has a tough road ahead showing that the survival benefit seen in Akeso's clinical trial in China will hold up in a global population.Immuneering, BMS/BioNTech, Merck, Pfizer and many more also scored oncology wins at the annual meeting, as did Moderna, with “encouraging” 5-year survival for its mRNA-based personalized melanoma vaccine. Outside of ASCO, the past week saw Pfizer strike an unusual pact with China's Innovent Biologics as it seeks to bolster its oncology pipeline. Reminiscent of another recent deal from BMS and Hengrui Pharma, it could signal a more collaborative approach to working with Chinese companies. We'll also cover the latest deals from Eli Lilly, which continues to rack up partners with its GLP-1 windfall. Finally, learn about how BrainStorm is planning another FDA bid for its experimental ALS therapy NurOwn with former regulator Peter Pitts now on the board, and check out a preview of the 2026 American Diabetes Association, or ADA, which kicks off this weekend in New Orleans.

On this week's episode, Chris Garabedian, Brian Skorney, Graig Suvannavejh, and special guest Ginkgo Bioworks CEO, Jason Kelly, kick off with a market update, highlighting a continued positive sentiment, citing Endpoints' recent Biopharma Sentiment Index survey results, which showed improvements in biopharma conditions. The co-hosts also note the continued IPO activity, including Kardigan's recent filing. The conversation shifts to China, with Jason suggesting that genetic engineering is a strategic technology extending beyond therapeutics, warning that the U.S. is offshoring critical innovation to China. This sparks a debate with others noting that global collaboration is embedded in drug development and questioning whether restricting partnerships would ultimately harm U.S. competitiveness. In deals, the group highlights Lilly's acquisition of three vaccine companies for up to $3.8 billion and Apogee's $1.3 billion strategic collaboration with Blackstone to advance their eczema drug. The conversation shifts to data, with GSK's Phase 3 data for chronic hepatitis B drug, and an overview of datasets at ASCO 2026, including Revolution Medicines Phase 3 trial results for pancreatic cancer, which are expected to be the headline of the conference. The episode concludes with an overview of Biohaven's R&D Day, BMS in multiple myeloma, Dyne's DMD, and updates on the FDA following the recent leadership changes. after the departure of Dr. Marty Makary. *This episode aired on May 29, 2026. 

Welcome to IDEA Collider. In this episode, host Alex Gray is joined by IDEA Pharma colleagues David Radwaner and Tom Brockbank to dissect the history, strategy, and future of immuno-oncology (IO). The trio explores how PD-1 and PD-L1 therapies revolutionized cancer treatment, acting as a brake on the immune system to offer unprecedented durability and long-term survival for patients.  They take a deep dive into the fascinating commercial and clinical race between Merck's Keytruda and BMS's Opdivo. Learn how Merck's strategic decisions—including smart statistical trial designs, targeted biomarker approaches in first-line non-small cell lung cancer, and tumor-agnostic labels like MSI-high—allowed Keytruda to secure market dominance. Finally, Alex, David, and Tom look ahead to the next ten years, discussing whether emerging players like AstraZeneca and China's Akeso / Summit will displace Keytruda, or if the future lies in combination therapies.    Episode Timestamps:  00:00:00 - Introduction: Meet David Radwaner, Tom Brockbank, and host Alex Gray.  00:01:45 - The Origins of IO: The Nobel Prize-winning discovery of PD-1 and CTLA-4 checkpoints.  00:03:55 - Why PD-1 / PD-L1 Won: The unique breadth of utility and unparalleled durability of long-term survival.  00:06:21 - Keytruda vs. Opdivo: How Merck's strategic trial design and smart statistical work outpaced BMS's early lead.  00:11:48 - The NSCLC Inflection Point: Why narrowing the patient population (PD-L1 - 50%) cemented Keytruda's foundation in first-line lung cancer.  00:14:20 - Tumor-Agnostic Success: Merck's bold move into MSI-high and broad biomarker-led strategies.  00:16:09 - Science or Luck? Analyzing Merck's aggressive and risky clinical development strategy.  00:18:00 - The Next 10 Years: Will anyone displace Keytruda? Assessing the future strategies of Merck, BMS, AstraZeneca, and Akeso/Summit    Don't forget to Like, Share, Subscribe, Rate, and Review!   Keep up with Alex Gray;  LinkedIn: https://www.linkedin.com/in/alexander-gray-934a653/    Keep up with David Radwaner;  LinkedIn: https://www.linkedin.com/in/david-radwaner-1b496343/    Keep up with Tom Brockbank;  LinkedIn: https://www.linkedin.com/in/tom-brockbank-159bb4116/      Follow IDEA Pharma On; Website: https://www.ideapharma.com/    Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

With co-author Chris Coyne, Abby Hall has a new book serving as an introduction to the Austrian School. As she and Bob discuss, the book fills a niche in the existing options of this genre.Mentioned in the Episode and Other Links of Interest:The YouTube version of this episode.Abby Hall's new book (co-authored with Chris Coyne), Austrian Economics: An Introduction.The prior BMS interview of Abby (on Latin American military intervention).Help support the Bob Murphy Show.

Thank you for joining us for our 2nd Cabral HouseCall of the weekend!   I'm looking forward to sharing with you some of our community's questions that have come in over the past few weeks…   Emily: Hi Dr Cabral, you are just such an amazing soul! Keep doing gods great work! I'm writing in to ask about my personal situation, I am 34, I had a throat cancer back in 2019, underwent radiation and surgery. Since then I had 2 babies, and came down with autoimmune symptoms this last year 2025. Since then I dove into healing myself, finished a gut program, did "big 5" labs, just did a 3 month mold detox. I am a year out and my food sensitivities are gone, brain fog gone, gut healed. But what is remaining is rosacea still, and I just did a teeth cleaning and we are still seeing inflamed gums. I am working with a practitioner and we know I have some viruses to tackle next and boost my immune system. At this point is there anything more you would add, to help me get rid of remaining rosecea?      Ashley: Hi Dr. Cabral! I installed the hydrogen water device you recommended in my home last summer. My family loves it, however whenever I personally drink the water I get SEVERELY constipated. I have run 4 tests now over the last 6 months and every time I reintroduce the water (even at a low pH and titrating up as advised by your team) the constipation returns. Ironically the very first week I tried the water I was having 3-4 BMs a day before the constipation trend began. Do you have any ideas what could be going on? I'm an IHP-L2 and have consulted your team and the support groups, but everyone seems perplexed... hence my outreach to you directly on this one. Note I did the CBO protocol 2x last yr for recurring gut infections before uncovering I have mold toxicity & am now on this protocol.      Brett: Hi Dr. Cabral—I'm seeking guidance on refractory hypercoagulability. I've had 77 DVTs and 33 pulmonary emboli, and was diagnosed with antiphospholipid syndrome two years ago. Despite therapeutic anticoagulation with daily Arixtra (fondaparinux), I continue to develop thrombotic events. Are there evidence-informed adjunct strategies (e.g., anti-inflammatory protocols, micronutrient optimization, endothelial support, or additional labs) that may help reduce clot recurrence alongside standard care? I remain under physician management but am exploring complementary approaches to improve outcomes. Thank you.       Kay: Dear Dr. Cabral- Thank you so much for the work you are doing and all your super informative podcasts. I took the Minerals & Metals test end of 2024 which showed high mercury and aluminum so in November of 2025 I had all 4 of my mercury amalgams removed by a biological dentist who is SMART certified. After removal, I did my Heavy Metal Detox for 8 weeks. I then retested at the beginning of April and just received my test results and was dismayed to see Mercury levels exactly the same and the aluminum slightly higher, even. Several other minerals were off balance as well. My question to you is how long would it take to detox from amalgam removals and should I do another heavy metal detox? Or did I retest too early? Appreciate your help, Kay       Kay: Hi Dr Cabral, Recently I had conventional bloodwork labs done and repeated (Mar 31st, April 3rd) testing high in magnesium levels (2.4 mg/dL and 2.5 mg/dL, respectively) and experienced symptoms of palpitations at night. My functional medicine Dr told me to stop taking any supplements/nutritional beverages containing Mg (i.e. CALM Mg powder) which I did. Even more of a surprise was when I received my recent Minerals & Metals test back, done around the same time as my blood tests, showing that I had an elevated Ca/Mg ratio (7.9) indicating relative Mg deficiency and elevated Na/Mg ratio (5.3) also indicating a relative Mg deficiency. How could both of these labs be true? Could stress play a factor? I recently moved and am caring for parents, 1 who has been Dx'd w/cancer.     Thank you for tuning into this weekend's Cabral HouseCalls and be sure to check back tomorrow for our Mindset & Motivation Monday show to get your week started off right!   - - - Show Notes and Resources: StephenCabral.com/3761 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!  

Jacob Townsend talks to Jeff Birchfield, of Six Rivers Media, about the passing of Kyle Busch, his career, legacy, success at BMS, and more.See omnystudio.com/listener for privacy information.

Hour 4 of May 22, 2026 Jacob Townsend talks to Jeff Birchfield, of Six Rivers Media, about the passing of Kyle Busch, his career, legacy, success at BMS, and more. Then, he discusses a split of opinions in the SEC about whether or not to go to 24 team College Football Playoff. Also, he talks about Greeneville playing in state championship today and the Lady Vols getting ready for the second game of their Super Regional. See omnystudio.com/listener for privacy information.

Synopsis: At the intersection of personal mission and biotech leadership, Rahul Chaturvedi sits down with Catherine Owen Adams, CEO of Acadia Pharmaceuticals, for a deeply personal and strategically rich conversation on leadership, commercialization, and the future of neuropsychiatry. From starting as a pharmacist in the UK to pivoting from R&D into commercial leadership at Johnson & Johnson, rising through Bristol Myers Squibb, and ultimately stepping into her first biotech CEO role at Acadia, Catherine shares how storytelling became the throughline of her career—transforming science into physician trust, investor conviction, and enterprise vision. In this episode, Catherine opens up about the personal family experiences with neurodegenerative disease that made Acadia's focus on CNS and rare disease feel like her “Goldilocks opportunity.” She offers a candid look at the realities of being a first-time CEO, managing investor ecosystems, building the right C-suite, balancing billion-dollar commercial execution with high-risk R&D, and navigating the emotional stakes of developing therapies for Parkinson's disease psychosis, Alzheimer's disease psychosis, Rett syndrome, and beyond. Rahul and Catherine also explore the seismic shifts reshaping biotech—from AI-powered commercialization and patient services to policy advocacy through BIO, FDA modernization, and the strategic pressures facing CNS innovation. This episode is both a masterclass in biotech leadership and a powerful reminder that the best CEOs don't just run companies—they tell stories that move science, markets, and patients forward. Biography: Ms. Owen Adams joined Acadia as Chief Executive Officer and as a member of our Board of Directors in September 2024. Ms. Owen Adams has over 25 years of executive level experience in the pharmaceutical industry. Prior to joining Acadia, Ms. Owen Adams served as Senior Vice President and General Manager, U.S., at Bristol Myers Squibb (BMS), where she led a $20 billion commercial business, overseeing a large and diverse portfolio of promoted brands across Oncology, Cardiovascular, and Immunology. Previously, Ms. Owen Adams held the position of Senior Vice President, Head of Major Markets at BMS, where she led commercial operations leading 6,000 employees across 19 countries in Europe, Japan, and Canada during BMS's merger with Celgene. Prior to her tenure at BMS, Ms. Owen Adams spent 25 years at Johnson & Johnson (J&J), where she held leadership roles across global, U.S., and European business units, with her last position being President, Janssen Immunology U.S. Ms. Owen Adams began her career in R&D and manufacturing at AstraZeneca. Ms. Owen Adams currently serves on the board of directors of Agios Pharmaceuticals, Inc., a publicly held company, and AssistRx, a privately held company. Ms. Owen Adams was formerly on the board of directors and chair of the compensation committee for Optinose PLC, a public specialty pharmaceutical company, and was on the board of directors of Robert Wood Johnson University Hospitals, a non-profit organization. Ms. Owen Adams earned a BSc. in Pharmacy from the University of Manchester, becoming a qualified pharmacist and member of the Royal Pharmaceutical Society (MRPhS).

La batería de un coche eléctrico no es un componente estático; es un laboratorio químico en constante ebullición y, lamentablemente, tiene fecha de caducidad. En este vídeo abrimos la "caja negra" de la degradación para explicar por qué el depósito de los coches eléctricos "encoge" con el tiempo y qué puedes hacer para evitarlo. ¿Qué es realmente la degradación? A diferencia de un motor de combustión, donde el depósito siempre tiene el mismo tamaño, las baterías de iones de litio sufren dos tipos de castigo constantes: -Degradación por calendario: El simple paso del tiempo oxida los componentes internos, incluso si el coche está parado en el garaje. -Degradación por ciclo: El estrés mecánico de cargar y descargar expande y contrae los materiales, generando microfisuras en los electrodos. Según datos actualizados a 2026, la pérdida media de capacidad se sitúa en un 2,3% anual. Esto significa que, en diez años, tu coche habrá perdido casi una cuarta parte de su autonomía original. Los tres enemigos de tu autonomía Para maximizar la vida útil de las celdas, debemos vigilar tres factores críticos: -El Calor: El litio sufre fuera de los 15°C - 35°C. El calor extremo acelera la descomposición del electrolito, creando una capa de "colesterol químico" que atrapa los iones y los deja inservibles. -La Carga Ultrarrápida: El uso sistemático de cargadores de más de 100 kW duplica la velocidad de degradación en comparación con la carga doméstica. Es un estrés térmico que la química paga caro. -Estados de Carga Extremos: Mantener el coche al 100% durante días o bajar habitualmente del 5% genera inestabilidad química y riesgos de fallos de voltaje permanentes. El peligro oculto: Las Dendritas Uno de los secretos mejor guardados es la formación de dendritas. Estas estructuras ramificadas crecen cuando se abusa de la carga rápida, especialmente en frío. Si una de estas "agujas" metálicas perfora el separador interno, se produce un cortocircuito que puede derivar en un incendio químico de extrema dificultad de extinción. La trampa del software (SOH) El "State of Health" o salud de la batería es un dato calculado por el software del fabricante (BMS). Hemos detectado casos donde las actualizaciones de software "maquillan" este porcentaje, liberando capacidad de reserva oculta para que el usuario no note la degradación real. Es vital certificar la salud de la batería con herramientas externas antes de comprar un eléctrico de segunda mano. Decálogo de Supervivencia: Cómo estirar la vida de tu batería Para evitar facturas de reemplazo que pueden oscilar entre los 7.000 € en coches urbanos hasta más de 25.000 € en modelos premium, sigue estos consejos: -Regla del 20-80: Mantén el uso diario en este rango. -Carga lenta: Prioriza siempre la carga en casa (AC). -Evita el 100% estático: Si cargas al máximo, que sea justo antes de salir de viaje. -Preacondicionamiento: Calienta la batería en invierno antes de circular o cargar. -Aparca a la sombra: Evita que el suelo caliente "cocine" las celdas. -Conducción suave: Evita picos de descarga por aceleraciones bruscas. -No llegues al 0%: Podrías dejar la batería en un estado de "sueño profundo" irreversible. -Freno regenerativo: Úsalo para recuperar energía de forma suave. -Actualizaciones: Mantén el software al día para mejorar la gestión térmica. -Certificación real: Usa dispositivos OBD2 para conocer el estado real de la química. La movilidad eléctrica actual exige un usuario consciente. Mientras no lleguen las baterías de estado sólido a finales de esta década, cuidar la química es la única forma de evitar que tu coche se convierta en un gasto inasumible.

Adam Haman returns to help Bob respond to Martyr Made's recent appearance on Jacob Winograd's Biblical Anarchy podcast.Mentioned in the Episode and Other Links of Interest:The YouTube version of this conversation.Darryl's appearance on Jacob Winograd's show.A previous BMS covering Oregon's drug decriminalization.This episode's sponsor, The Swan Brothers.The HamanNature substack.Help support the Bob Murphy Show.

Agradece a este podcast tantas horas de entretenimiento y disfruta de episodios exclusivos como éste. ¡Apóyale en iVoox! En este episodio de La Ola Eléctrica nos adentramos en uno de los temas más importantes, y a la vez menos comprendidos, del coche eléctrico: las baterías. Durante décadas, el motor fue el corazón del automóvil. Pero en la era eléctrica, el centro de poder se ha desplazado bajo el suelo del vehículo. La batería decide la autonomía, el precio, la carga rápida, la vida útil, la seguridad, el peso y hasta la estrategia industrial de países enteros. Hablamos de cómo funciona una batería de coche eléctrico, qué elementos la componen, qué papel tienen el ánodo, el cátodo, el electrolito, el separador y el BMS, y por qué no todas las baterías son iguales. Analizamos las principales tecnologías actuales: LFP, NCM, NCA, LMFP, baterías de sodio y las prometedoras baterías de estado sólido. También explicamos por qué China ha tomado tanta ventaja con gigantes como CATL y BYD, por qué Europa ha reaccionado tarde, qué papel juegan materiales como el litio, el níquel, el cobalto, el grafito o el sodio, y por qué el reciclaje será clave en la próxima década. Un episodio para entender que la batería no es solo un componente más del coche eléctrico: es el nuevo motor, el nuevo campo de batalla industrial y una de las claves que decidirán qué marcas y qué países liderarán la movilidad del futuro.Escucha este episodio completo y accede a todo el contenido exclusivo de Somos Eléctricos. Descubre antes que nadie los nuevos episodios, y participa en la comunidad exclusiva de oyentes en https://go.ivoox.com/sq/627406

Podcast: PrOTect It All (LS 27 · TOP 10% what is this?)Episode: Cyber Risk in Construction: Securing AEC Projects in a Digital, AI-Driven WorldPub date: 2026-04-27Get Podcast Transcript →powered by Listen411 - fast audio-to-text and summarizationConstruction sites are no longer just physical - they're digital, connected, and increasingly vulnerable. In this episode of Protect It All, host Aaron Crow sits down with Lee Carsten to explore the rising cyber risks across the architecture, engineering, and construction (AEC) industry. As digital transformation accelerates - with AI, digital twins, and connected building systems becoming standard - construction projects are expanding their attack surface in ways many organizations don't fully understand. Aaron and Lee unpack the unique challenges facing AEC environments, from fragmented systems and evolving workflows to the growing need for integrating cybersecurity into business decisions - not just IT functions. You'll learn: Why construction and infrastructure projects are becoming prime cyber targets How digital transformation and AI are reshaping risk in AEC environments The role of building management systems (BMS) and OT in modern projects Why foundational controls and human awareness still matter most How to align cybersecurity with real-world construction workflows Practical strategies to build resilience into projects from day one Whether you're in construction, engineering, IT, or OT security, this episode delivers real-world insights to help you protect the infrastructure we rely on every day. Tune in to learn how to secure modern construction in a connected world - only on Protect It All. Key Moments:  05:39 Importance of interpersonal skills 08:08 Construction security and recent projects 11:46 Challenges in AEC industry adoption 19:30 Importance of disaster recovery 20:31 Discussing costs of business interruptions 24:06 RFP process and bid management 27:25 Complexity of building projects 32:02 FBI investigation triggers and readiness 36:55 Managing complex building assets 39:37 Choosing durable equipment and future tech 42:01 Understanding OT data for security About the guest :  Lee Carsten's journey in technology began in the era of punch cards - painstakingly sorted and fed into compilers, where a single fumble could mean hours' worth of work undone. Lee studied COBOL in college, envisioning a future as a programmer. That path nearly led to Walmart, where Lee's mother worked on the company's pioneering buyer decision support system under Randy Mott. While the family connection and an offer from Kevin Turner to join a new team were tempting, Lee ultimately decided against moving to Bentonville and working for $18,000 annually. This early exposure to large-scale business technology, combined with pivotal career choices, shaped Lee Carsten's perspective on IT and the evolving world of software development. How to connect Lee: https://www.linkedin.com/in/leecarsten/ Website: https://whitecaprisk.com/ Connect With Aaron Crow: Website: www.corvosec.com  LinkedIn: https://www.linkedin.com/in/aaronccrow Learn more about PrOTect IT All: Email: info@protectitall.co  Website: https://protectitall.co/  X: https://twitter.com/protectitall  YouTube: https://www.youtube.com/@PrOTectITAll  FaceBook:  https://facebook.com/protectitallpodcast To be a guest or suggest a guest/episode, please email us at info@protectitall.co Please leave us a review on Apple/Spotify Podcasts: Apple   - https://podcasts.apple.com/us/podcast/protect-it-all/id1727211124 Spotify - https://open.spotify.com/show/1Vvi0euj3rE8xObK0yvYi4The podcast and artwork embedded on this page are from Aaron Crow, which is the property of its owner and not affiliated with or endorsed by Listen Notes, Inc.

This week, Jimmy and Tyler catch up on two very different 4Runner projects — and somehow both of them involve things that were bent, broken, or seized in ways nobody’s seen before. Jimmy’s 4Runner “Samantha” is making progress. He spent the week fabricating temporary shock towers out of scrap steel, getting the shocks roughly mounted, and articulating the suspension to figure out how much travel he’s actually working with. The verdict: he needs to raise the shocks about a half inch, the bump stops are in the right ballpark, and the Panhard bar collision he was worried about looks like it won’t be an issue once the setup is dialed. He also talks through the surprisingly useful difference between working with metal vs. wood — and why metal scrap is genuinely hard to throw away. Tyler’s 4Runner “The Mule” went to Jason at OCD Innovations for a full teardown, and what they found was wild. The pinion bearing had seized and welded itself to the housing — which is what caused the axle lockup and the subsequent catastrophic failure. The good news: the Mile Marker hubs actually survived and held. The not-so-good news: basically everything else needed replacing — lower links (bent aluminum), upper link bracket, CV joints (Metal Cloak), steering kit (Sidetrack Off Road), DOM tubing for the track link and Panhard bar, and a driveshaft joint that exploded and saved the front diff case in the process. The one remaining unknown is the rear diff. Jason is being thorough — almost comically so — and the mule is back on four wheels, running under its own power. Registration still has to happen, which means blinkers, safety inspection, and a Switch-Pros wiring job are all still on the list. They also get into a deep conversation on lithium battery setups — starter battery vs. auxiliary battery, how alternators interact with lithium BMS shutoffs, and why Tyler is landing on a Dakota Lithium battery with a DC charger as his power management strategy. Off the trail: Jimmy went and saw *Project Hail Mary* in theaters and loved it (verdict: great home watch, doesn’t require the big screen). He ran a 10K at the Run Rockland event and surprised himself with a 9:45/mile average. And both Jimmy and Tyler took a moment to geek out over the Big Boy steam locomotive #4014 rolling through Roseville — 1.2 million pounds, 133 feet long, 7,000 horsepower, and apparently enough to stop traffic and make kids forget trains exist in favor of radio towers. SnailTrail4x4 Discord: https://discord.gg/yFyFFkQbuyCome hang out with us on the SnailTrail4x4 Discord — it’s the easiest way to connect with Tyler and Jimmy directly, chat with fellow offroad enthusiasts, and get first access to Group Buys and Treasure Hunt token drops. Group Buy for the Devos LightRanger 500We reached out to Devos, and they are in. Here’s how the discount tiers work: 10 people → 15% off (~$60/light) 20 people → 20% off (~$56/light) 30+ people → 25% off (~$52/light) These retail at $70. To get in, just send us your email and how many units you want. You can email us at jimmy@snailtrail4x4.com or tyler@snailtrail4x4.com, or DM us on Instagram. Deadline: April 30th. Want to learn more about the LightRanger 500? Click Here: https://www.devosoutdoor.com/products/lightranger-500 MORRFlate Giveaway at 900 Reviews on Apple Podcast. But our next giveaway is when we reach 800 reviews; we are giving away an OnX Elite Membership. We will also give away an OnX Elite membership when we get to 850. However, when we reach 900 Reviews, we are teaming up with MORRFlate for a $1000 MF Product Giveaway. Go over to Apple Podcasts to leave your review now and become eligible to win. Congratulations to A13XMONT, who won a set of tires from Yokohama Tire! Call us and leave us a VOICEMAIL!!! We want to hear from you even more!!! You can call and say whatever you like! Ask a question, leave feedback, correct some information about welding, say how much you hate your Jeep, and wish you had a Toyota! We will air them all, live, on the podcast! +01-916-345-4744. If you have any negative feedback, you can call our negative feedback hotline, 408-800-5169. 4Wheel Underground has all the suspension parts you need to take your off-road rig from leaf springs to a performance suspension system. We just ordered our kits for Kermit and Samantha and are looking forward to getting them. The ordering process was quite simple, and after answering the questionnaire, we ensured we got the correct and best-fitting kits for our vehicles. If you want to level up your suspension game, check out 4Wheel Underground. SnailTrail4x4 Podcast is brought to you by all of our peeps over at irate4x4! Make sure to stop by and see all of the great perks you get for supporting SnailTrail4x4! Discount Codes, Monthly Give-Always, Gift Boxes, the SnailTrail4x4 Community, and the ST4x4 Treasure Hunt! Thank you to all of those who support us! We couldn’t do it without you guys (and gals!)! SnailSquad Monthly Giveaway For the Month of April, we are giving away Gift Boxes. Its Gift Box month and two luck indiviuals will win a one of our gift boxs. These are jam packed with goodies from tools to whiskey smokers. They are always different and always random. If you want a chance to win, sign up for the Giveaway Tier on Irate4x4 Congrats to Roger Lutz on March’s Giveaway. We gave away the new Devos LightRanger500. This little light is jam-packed with features, from red, orange, and white lights to a motion sensor. It would be perfect for inside a tent, under a canopy, or just general use around the vehicle. If you want a chance to win, sign up for the Giveaway Tier on Irate4x4 Listener Discount Codes: SnailTrail4x4 –SnailTrail15 for 15% off SnailTrail4x4 MerchMORRFlate – snailtraill4x4 to get 10% off MORRFlate Multi Tire Inflation Deflation™ Kits4WheelUnderground – snailtrail 10% offIronman 4×4 – snailtrail20 to get 20% off all Ironman 4×4 branded equipment!Sidetracked Offroad – snailtrail4x4 (lowercase) to get 15% off lights and recovery gearSpartan Rope – snailtrail4x4 to get 10% off sitewideShock Surplus – SNAILTRAIL4x4 to get $25 off any order!Mob Armor – SNAILTRAIL4X4 for 15% offSummerShine Supply – ST4x4 for 10% offBackpacker’s Pantry – Affiliate LinkLaminx Protective Films – Use the Link to get 20% off all products (Affiliate Link) Show Music: Outroll Music – Meizong Kumbang Midroll Music – ComaStudio

Bob continues his commentary on John chapter 3, this time on verses 18 through 36 (finishing the chapter). The emphasis is on the humility of John the Baptist, and the fact that you need a savior.Mentioned in the Episode and Other Links of Interest:The previous episode in this series, i.e. BMS ep 487, Installment 11: Whoever Believes in Him.RC Sproul on Jesus as the light.Help support the Bob Murphy Show.

If you've ever found yourself wondering, "What is happening to me?"… you are not alone. Perimenopause can feel like a slow and disorienting shift. In this honest and empowering episode, I'm joined by Dr Charlotte Gooding, GP and BMS-accredited menopause specialist, to explore perimenopause, HRT and breast cancer risk. We unpack the symptoms many women miss, the emotional impact of hormonal change, and the nuance around HRT safety, so you can make more informed, personalised decisions about your health. If you're navigating perimenopause, HRT decisions, or breast cancer fears, this episode will help you feel more informed, empowered and less alone. More details: https://luminate-group.co.uk/podcast/183 Connect on LinkedIn Here  Follow on Instagram Here  Love the Wisdom For Working Mums Podcast? Let's take the conversation further. Subscribe for exclusive insights delivered straight to your inbox - designed to support you in leading with confidence and living with intention. 

Nard engages with the BMS chatroom and basically becomes a listener, cheat fantasies and more!

This Biotech CEO Created The RedTail Platform To Fight Cancer. Guest:Eric PomaCEO of Calidi Bio CLDI Company Name:Calidi BiotherapeuticsWebsite: https://www.calidibio.com/Ticker: NYSE: CLDIEric's Bio:Eric Poma, Ph.D. has served as Chief Executive Officer and board director of Calidi since April 2025 and brings more than 30 years of experience in the biopharmaceutical industry, with a strong record of capital fundraising, big pharma collaboration agreements, and clinical program development.Prior to joining Calidi, Dr. Poma served as CEO of Molecular Templates (NASDAQ: MTEM), a clinical-stage biotech focused on the development of a novel class of therapeutic agents with unique biology in oncology. At Molecular Templates he raised over $250 million in equity financing and secured over $150 million in strategic capital through agreements with Takeda, Vertex and BMS. He previously served as Vice President, Business Development of Innovive Pharmaceuticals. Prior to that he held various senior level positions at Imclone Systems, Inc., primarily in business development. Earlier, Dr. Poma served as a Healthcare & Biotechnology Analyst with the healthcare fund Eagle Growth Investors, LLC.Dr. Poma received a Ph.D. in Microbiology and Immunology from the University of North Carolina at Chapel Hill, an M.B.A. from the Leonard N. Stern School of Business and a Bachelor of Science in Biology from the University of North Carolina at Chapel Hill.Company Bio:Calidi Biotherapeutics is a biotechnology company pioneering the development of targeted genetic medicines for cancer and other diseases through its RedTail platform. The company's lead compound, CLD-401, is a systemically delivered oncolytic virus that expresses high levels of IL-15 superagonist only in the tumor microenvironment. The company expects to file an IND to initiate clinical studies for CLD-401 by the end of 2026. The company continues to advance what the RedTail platform can achieve and will be presenting additional data throughout the year.

In this episode, we welcome Kirollos Hanna, PharmD, BCPS, BCOP, a recognized leader in oncology pharmacy practice and research. Dr. Hanna shares insights into the evolving landscape of antibody-drug conjugates (ADCs) and the unique challenges they present in managing chemotherapy-induced nausea and vomiting (CINV).  As ADC use expands, oncology teams are observing new and sometimes underrecognized patterns of nausea and vomiting, particularly with HER2-directed therapies and delayed-phase symptoms that extend beyond the traditional monitoring window. This discussion highlights how these patterns differ from conventional chemotherapy and what that means for clinical practice.  Dr. Hanna also reviews emerging pharmacokinetic data and clinical trial evidence supporting the use of NK1 receptor antagonist–based antiemetic strategies. The conversation emphasizes practical, actionable approaches for optimizing supportive care, improving patient quality of life, and ensuring proactive symptom management within the medically integrated oncology team.  Learning Objectives:  Describe emerging patterns of chemotherapy-induced nausea and vomiting (CINV) associated with antibody–drug conjugates (ADCs), with emphasis on HER2-directed ADCs and delayed-phase nausea beyond day 5  Discuss pharmacokinetic and clinical trial evidence on NK1 receptor antagonist–based antiemetic strategies when optimizing CINV prevention for patients receiving ADC therapy.  This episode offers 0.5 CE credit hours to pharmacists and pharmacy technicians. Claim CE credit here. Guest: Kirollos Hanna, PharmD, BCPS, BCOP, Director of Pharmacy, Minnesota Oncology, Assistant Professor of Pharmacy, Mayo Clinic College of Medicine, Associate Editor, Journal of the Advanced Practitioner in Oncology (JADPRO)  Disclosures: Speaker: BeOne, BMS, Exelixis, Pfizer Consulting Fees: BeOne, BMS, Exelixis, Pfizer, Astrazeneca

Bob was recently on the "What Is Money?" podcast to probe the philosophical underpinnings of Austrian economics.Mentioned in the Episode and Other Links of Interest:The YouTube version of this interview.HHH's Economic Science and the Austrian Method (ESAM).BMS ep 7 explaining Godel's theorem.Bob's earlier appearance on "What Is Money?" (recorded on-site at the inaugural ARC conference).Help support the Bob Murphy Show.

Te vamos a contar toda la verdad en 2026. ¿Es cierto que un fallo en la batería significa el fin de la vida útil de un coche eléctrico? Esta es la pregunta del millón que frena a muchos compradores y quita el sueño a otros tantos. La creencia popular dice que cualquier avería en el acumulador de energía implica un gasto de 20.000 euros o el desguace inmediato, pero la realidad técnica y financiera es mucho más compleja y, afortunadamente, más optimista. La anatomía de la "caja negra" Para entender si una batería se puede reparar, primero hay que saber qué hay dentro. No estamos ante un bloque sólido e indivisible. Una batería de tracción se compone de tres niveles: las celdas (la unidad mínima), los módulos (agrupaciones de celdas) y el pack (el conjunto total con su carcasa, refrigeración y el cerebro electrónico o BMS). En la mayoría de los casos, "reparar" consiste en identificar el módulo defectuoso y sustituirlo, evitando el coste astronómico de cambiar el pack completo. La economía de la reparación La decisión de reparar no es solo técnica, es puramente financiera. En 2026, los precios de las baterías han bajado significativamente, rondando los 130-150 €/kWh. Por ejemplo, una batería nueva de un Renault ZOE puede costar unos 7.500 €, mientras que la de un VW ID.4 sube hasta los 16.500 €. Si la sustitución de un módulo ronda los 2.000 €, el ahorro es evidente. Sin embargo, hay que tener en cuenta el "State of Health" (SOH) o estado de salud general. Si el resto de la batería está muy degradado, poner un módulo nuevo es inútil, ya que se descompensará rápidamente con los antiguos. Arquitectura y reparabilidad: No todos los coches son iguales Aquí es donde los fabricantes toman caminos distintos. El diseño del coche determina si la reparación es sencilla o una pesadilla: -BMW i3: Un ejemplo de diseño inteligente con 8 módulos independientes y accesibles. -Grupo Hyundai/Kia: Su plataforma E-GMP permite sustituir secciones con relativa facilidad, bajando costes de mano de obra. -Tesla (Model Y con celdas 4680): El polo opuesto. Al usar baterías estructurales rellenas de resina (foam) para dar rigidez, la reparación es prácticamente imposible. Si falla, se cambia el pack entero. -Toyota y Lexus: Especialistas en longevidad, sus baterías de níquel-metal hidruro son las más reparadas del mundo gracias a su sencillez. Curiosidades y el futuro del sector El debate sobre la reparación no es nuevo. Ya en 1900, el Lohner-Porsche (el primer híbrido) sufría con sus pesadas baterías de plomo. Hoy, vemos fenómenos como los "Tesla resucitados" en Europa del Este, donde mecánicos expertos y hackers consiguen reparar packs que la propia marca da por perdidos, "engañando" al software para devolver los coches a la carretera. Mirando al futuro, las baterías de estado sólido prometen más autonomía, pero plantean un reto: al ser bloques sólidos, su reparabilidad podría ser nula. Por contra, gigantes como CATL están estandarizando módulos para que los talleres independientes puedan comprar recambios originales, lo que reduciría los costes de reparación hasta un 80%. ¿Cuándo es mejor no intentar la reparación? Existen tres escenarios donde lo más sensato es desistir: -Degradación uniforme: Si todas las celdas están agotadas por igual. -Daños por inundación: La corrosión interna por agua es un "cáncer" imposible de frenar en el litio. -Coste excesivo: Si la factura supera el 60% del valor venal del coche. En conclusión, reparar una batería es hoy una opción real y viable siempre que el fallo sea localizado y el resto del conjunto esté sano. La "muerte" de la batería ya no es el fin del coche, sino una avería importante pero gestionable dentro del nuevo ecosistema de la movilidad eléctrica.

Michael Fraser is a business consultant on leading LLMs, with an extensive knowledge of praxeology. He joins Bob to discuss the Pentagon's decision to sever ties with Anthropic and even designate them a supply chain risk.Mentioned in the Episode and Other Links of Interest:The YouTube version of this interview.Anthropic CEO's statement in response to Hegseth decision.Academic paper putting leading LLMs into a wargame.Good examples of "jailbreaking" safeguards on LLMs.The BMS interview of Steve Landsburg discussing Grothendiek.Michael Fraser's interview on the InFi podcast, discussing LLMs as a cauldron, not a crystal ball.Help support the Bob Murphy Show.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.We start with a significant personnel change at the FDA, where Vinay Prasad, M.D., is set to depart by the end of April. Known for his contentious interactions with the biopharma industry, particularly concerning vaccines and cell and gene therapies, his departure may signal shifts in regulatory priorities and approaches. Industry stakeholders are closely watching how his exit will affect upcoming decisions and relations between regulatory bodies and biopharma companies.In a strategic collaboration, Novo Nordisk and Hims & Hers have settled their public disputes by agreeing to distribute Novo's Ozempic and Wegovy through Hims' telehealth platform. This partnership highlights the increasing importance of digital health platforms in expanding medication access, particularly for chronic conditions like obesity and diabetes. This trend reflects a broader movement where legacy pharmaceutical companies are turning to digital avenues to enhance patient reach.On the clinical trial front, Ipsen has decided to halt the development of its lymphoma drug Tazverik after safety concerns were raised by an independent data monitoring committee. This decision underscores the rigorous safety standards in place for clinical trials and the ongoing challenge of balancing potential therapeutic benefits against safety risks. Similarly, Roche's oral SERD giredestrant failed to meet its primary endpoint in a phase 3 trial for first-line breast cancer treatment, raising questions about the limits of selective estrogen receptor degraders despite previous successes in adjuvant and second-line settings. The complexity of translating promising mechanisms into consistent clinical outcomes across different stages of treatment is highlighted here.Regulatory challenges remain a significant theme, with Novo Nordisk's Indiana plant facing scrutiny that led to the FDA rejecting Incyte's application for Zynyz as a first-line treatment for non-small cell lung cancer. This incident underscores how manufacturing issues can heavily impact drug approval processes and highlights the critical nature of compliance with regulatory standards.In terms of new drug approvals, Bristol Myers Squibb has received FDA approval for Sotyktu, a first-in-class oral TYK2 inhibitor for treating psoriatic arthritis. This approval not only broadens treatment options for patients but also reinforces the ongoing trend towards developing targeted therapies with novel mechanisms of action. Additionally, Bristol Myers Squibb is gaining momentum with its cereblon E3 ligase modulator (celmod), mezigdomide, achieving statistically significant improvement in progression-free survival among multiple myeloma patients in a Phase 3 trial. This success solidifies BMS's position in hematologic oncology and demonstrates the potential of targeted protein degradation as a therapeutic strategy.The industry is also witnessing significant financial transactions and restructuring efforts. Lonza's decision to sell a majority stake in its capsule business to Lone Star Funds for $3 billion reflects strategic realignments as companies focus on core competencies while leveraging partnerships to optimize business operations.Meanwhile, regulatory scrutiny persists as Democratic lawmakers are investigating 11 pharmaceutical companies regarding their pricing agreements under the previous administration's "most favored nation" clause. This inquiry aims to understand whether these deals have indeed resulted in cost savings for Medicaid, highlighting ongoing concerns about drug pricing transparency and affordability.In another strategic move aimed at bolstering innovation, Regeneron reported promising results from a phase 3 trial conducted by its Chinese partner on a drug mirroring Zepbound's efficacy in obesity treatmenSupport the show

Early STEM experiences impact the innovators of tomorrow. Mike Sherman of Bristol-Myers Squibb shares how the company champions community engagement through events like Super STEM Saturday, offering students across San Diego hands-on science activities and access to diverse role models. From lab demonstrations to interactive experiments, the conversation highlights how real-world STEM exposure can spark curiosity, build confidence, and show students from all backgrounds that a future in science is within reach.Bristol Myers Squibb's mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases—pursuing bold science to define what's possible for the future of medicine and the patients we serve. For more information, visit BMS.com and follow on LinkedIn, X, YouTube, Facebook, and Instagram.

Dr. Pedro Barata and Dr. Kathryn Schmitz discuss evidence-based exercise oncology programs, how to incorporate exercise into cancer care and connect the right patient to the right program, and ultimately build a culture of exercise in oncology. TRANSCRIPT Dr. Pedro Barata: Hello, and welcome to By the Book, a podcast series from ASCO that features compelling perspectives from authors and editors of the ASCO Educational Book. I'm Dr. Pedro Barata. I'm a medical oncologist and a clinical trialist at the University Hospital Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also happy to serve as a deputy editor for the ASCO Educational Book. Today, we'll be talking about exercise. We have plenty of evidence that exercise benefits symptoms, improves the quality of life of patients, and actually has been shown to reduce risk of recurrence of cancer but also improve survival. And I think that's increasingly clear as data emerges. Today, I'm delighted to be speaking to Dr. Kathryn Schmitz. She's a leading expert on integrating exercise into cancer care. Dr. Schmitz serves as the deputy director of the University of Pittsburgh Hillman Cancer Center and also a professor of hematology-oncology at University of Pittsburgh Medical School. She's the senior author of a fantastic article in the ASCO Educational Book that's titled "Implementation Science as the Secret Sauce for Integrating Exercise Screening and Triage Pathways in Oncology." She also led a really compelling piece that just got published in JCO titled "If Exercise Were a Pill, We'd All Prescribe It to Patients With Cancer. But It's Not" So I'm thrilled to have Dr. Schmitz joining us today and helping us explore evidence-based exercise oncology programs, how to incorporate exercise into cancer care, and also how to connect the right patient to the right program.  So with that, welcome, Dr. Schmitz. Thank you so much for taking the time to chat with us. Dr. Kathryn Schmitz: Thank you for the opportunity. Dr. Pedro Barata: One of the highlights of ASCO last year and practice changing, in my opinion, data out of The New England [Journal of Medicine] is called the CHALLENGE trial. It did provide high level evidence that a structured, supervised exercise program could improve both disease-free survival and overall survival. This is a study in the GI world, but I think it got a lot of attraction and attention beyond the GI world, across solid tumors, really. Could you give us a little brief recap of that trial and what have you seen as being the impact in practices around oncology? Dr. Kathryn Schmitz: So, CHALLENGE was very exciting. Prior to CHALLENGE, there were any number of observational studies that indicated that there was a relationship between being more physically active and reduced recurrence and improved overall survival for colon cancer in particular. You know, notably, in 2006, Jeff Meyerhardt published two papers in the same journal, of the same issue of JCO, showing very, very similar data from two very large studies. And those were studies number five and six in this area. You know, there's a lot of evidence observationally, but we don't generally change clinical practice on the basis of observational data. So, we were all waiting very impatiently for the results of the CHALLENGE trial. And it was very exciting to be in the front row when the results were reported out and to be part of the group with a standing ovation for the authors when it was presented. To summarize, 889 colon cancer patients, stage II and III, were randomized into either a structured exercise program or a health education control comparison group and followed for an average of 7.9 years. And the structured exercise group had a 27% reduced risk of recurrence and a 38% improvement in overall survival. One of the things that's really notable about this is that what we typically expect is that when we go from the observational literature to the clinical trial literature, that we expect effects to go down. We expect to see a larger effect in the observational than in the RCT land, and that did not happen here. We actually see an effect that matches what we've seen in observational literature, which is really, really exciting.  And, you know, one of the reasons why this has been so exciting across not just GI but other cancers is the notable finding of a reduced risk of second primaries. So, they only observed two breast cancer second primaries in the treatment group and 12 in the comparison group. And overall, they reduced the second primaries occurrence, hazard ratio was 0.5, a 50% reduction of second primaries, which is just remarkable. It really got everybody very, very excited. And now the big question, of course, is, all right, how do I do this? How do I make this happen?  The thing to note is that what they did in CHALLENGE is probably not doable in your clinic tomorrow. It's a heavy intervention. The number of touchpoints from staff is extensive, and the amount of time needed from staff for the coaching and supervised exercise is extensive as well. The criteria for getting people into the program required that people go through a series of blood tests and imaging tests that would just simply not be possible for the average community oncologist. So I'm guessing that you're going to ask me some questions about how we do this. Dr. Pedro Barata: Right. That's a fantastic segue. That's exactly right. Walk us through maybe starting by, what does that mean? Dr. Kathryn Schmitz: The first thing to say is I have to go back to the observational literature. And the observational literature shows really compellingly that we have a strong reduction of breast cancer recurrence and mortality from being more physically active, prostate cancer recurrence and mortality, and colon cancer recurrence and mortality. I find it very difficult to believe in this day and age, in our current environment, if you will, that we are ever going to have the equivalent of CHALLENGE for prostate or for breast cancer. There is an ongoing study in prostate that's led by some Australian researchers, but I just don't think that it's likely that we're going to mount something similar for another tumor site. We have tremendous correlative data that indicates that there are a number of biomarkers and biological pathways through which breast, colon, and prostate cancer would be reduced in recurrence if people were more physically active. And so, there is really, from my thinking, very little to state that it would be just a colon cancer effect. And so this is something we probably can enact in more than just the colon cancer community, overall, which is great news, and it makes it easier for us to be able to enact this type of programming. Dr. Pedro Barata: One of the things that comes up perhaps often is, if I were the leader of the cancer center and were to incentivize the different care teams to implement an exercise program at each level: GI team, GU, breast, thoracic, etc. How do we do that? Dr. Kathryn Schmitz: So, I want to give you an analogy. You're a medical oncologist, and you prescribe your patients chemotherapy. Now, just imagine, if you will, what would happen and how likely it would be for your patients to get chemotherapy if there was no chemoinfusion suite. If the chemoinfusion suite disappeared tomorrow and you were to tell your patients, "Go get some chemotherapy," what proportion of those patients do you think would go find all of the equipment necessary and all of the drugs necessary and understand how to dose the chemotherapy for themselves and get that all done? Very few people would do it. So with exercise, why would we be surprised then that our patients don't actually do a whole lot if we just simply tell them to go get some exercise? Exercise is a medicine. It is effective like a medicine. We've shown this through the CHALLENGE trial and many other correlative studies and an ocean of observational data as well. So the question is, how do we build the infrastructure that is necessary in order for your patients to do this? So the very first thing that has to happen is that somebody has to tell the patient to exercise. We currently do not have a culture of exercise in oncology. We do in heart disease. If you ask the average person on the street, "Is exercise good for your heart?" Anybody with an eighth-grade education is going to say, "Yes, of course," because the American Heart Association has done an amazing job telling everybody that exercise is good for your heart. But what has ASCO done, frankly? Can I be that bold? What has ASCO done to tell patients that they should be exercising during and after their cancer treatment? I'm not sure that I know more than a guideline. There is a guideline, and that's great. And the guideline is very helpful, but I'm not sure that patients know that there's a guideline. In fact, I can tell you that patients don't know that there is a guideline. So, you know, making sure that there's a paradigm shift in the country that says exercise is good for patients during and after their cancer treatment is the first step. The second step is getting a medical professional to say something to the patient about the exercise. And I'm very careful with the two words that I just chose: medical professional. I do understand medical oncologists are very busy. I understand that there's a whole lot to say in that 15 minutes when you're with the patient. And so maybe it isn't the medical oncologist. Ideally, it would be, but I get it that there's limited time. So it could be a nurse practitioner, it could be a nurse, there could be a social worker, it could be somebody else on the team that says, "Hey, you know, we want you to do an exercise program. We want to connect you to an exercise program." And then there's what is the program itself? You know, I'm very interested in this happening across the entire country. And so I've been working with the leadership of the Commission on Cancer on the question of, well, how would you do this in community oncology? You know, it's not enough to do it in academic medicine, but how do you do this in community oncology? And you can't expect that every community hospital is going to build a gym for their cancer patients. That is just not reasonable to do. So, we start to try to figure out some phone counseling. Could we give people Fitbits and follow them? Could we use technology to help us? Are there telehealth opportunities for us to do? Are there apps that have been built? In fact, there is a [free] app called Cancer Exercise that's on, you know, all of the platforms and available to patients. So there are programs. I've developed a directory of over 2,000 programs that exist across the country for exercise oncology that patients can find, medical oncologists can find.  So there are a lot of people trying to figure out how best to get the information to medical oncologists and other medical professionals so that they can have an 'easy button' to be able to connect their patients to existing programming so that you don't feel like you have to build a whole new program. Dr. Pedro Barata: If I don't have the resources around me, what would be your advice for the care team or for the providers that might not have that available at their site? Where do they start? Who do they reach out to? Who should they be looking at to get more information on how to set it up? Dr. Kathryn Schmitz: I lead an international consortium called Moving Through Cancer. You can find us at movingthroughcancer.org. That's where you'll find the map of all of the programs across the country and the directory. We actually have a triage tool that sits at the front of the directory that allows people to discern what type of exercise they're safe to do. We do recognize that, you know, the 80-year-old that fell last week doesn't need the same program as the 35-year-old that was playing pickleball the day before diagnosis. So, you know, there are different kinds of programs for people at different levels of acuity. We're happy to be helpful to folks to help them set up programs.  But the number one thing is to really be very aware of the power of saying something about doing exercise, just simply the power of saying, "I want you to be moving." Because frankly, I don't think anybody listening to this would disagree, no one benefits from sitting on the couch all day, no one. No one, no one. It doesn't matter how acute their medical issues are. We get people out of bed. We try to move people even when they're in the hospital. So I think saying something is huge. And then, if you can, applying a triage tool, if you can get something embedded within your clinical flow so that you can understand who it is that needs to go to physical therapy as opposed to who's ready for an exercise program. Those are the two things. So triage and referral is kind of step one. And if you can get that done, the rest will fall into place. Dr. Pedro Barata: This is really powerful message, where one, awareness of the care teams. Number two, bring it up to the patient. And then working on the referral, triage and referral process. That's fantastic. Another aspect that comes up quite a bit is like, "Look, this is great, but we have a system that relies on payers to make things happen, or at least to get them approved." And that can be very different or heterogeneous. The coverage can be different. Sometimes already going through a system programs for interventions, therapeutic interventions, let alone probably the insurance is not going to cover that. Is that true? Is it not true? How do you walk through the different insurance supports, perhaps, depending on where you're practicing? Dr. Kathryn Schmitz: You've just hit on the hot button. I've been working on this issue for about nine years now, trying to figure out using efforts to talk to CMS and see if we can get third party payer coverage going. We were making good progress there, and there was a change of administration and a new focus on "Make America Healthy Again," the MAHA movement. And, you know, CMS is really no longer interested in one-off national coverage determination. They instead, they want to know, "How do we make exercise happen for every American over 65?" And my question is, "Well, wait a minute, cancer patients are not just older patients. There's a lot going on there. They need something special." So I've been working on that. It's been working with accrediting bodies for policy with a little p. Very proud of the work that I've done in collaboration with the National Accreditation Program for Breast Centers, trying to get standards to get exercise referrals for breast patients. And I'm currently holding my breath to see whether the CoC is going to try to make some forward motion in this area as well, crossing all period appendages, waiting for news there. So it's not paid for unless it's done by a physical therapist. And, you know, there's published evidence and I have plenty of evidence from UPMC as well, that people don't really want to go to the physical therapist for this. I'm not saying physical therapists aren't great. Physical therapists are great, and there are people who really need to go to physical therapy, and we try hard to get those patients connected. But for the patients that are ready for something more than physical therapy, we really have an uphill battle to try to figure out what insurers are willing to pay for and what the return on investment is.  One of the challenges with the return on investment is that the timeline, time course for return on investment for American insurers is about one year. And I'll remind you that the time course for return on investment for CHALLENGE was 7.9 years. So we have a mismatch there. So we're trying to figure out if we can produce the evidence to show that there is an improvement in unplanned health care utilization. We have documented that for breast cancer. We're working on it for other cancers. If we can document that it is worthwhile to the insurer to pay for these programs, then I believe that they will pay for them. You know, my conversations are very positive with UPMC, which is a very large insurer and a large health plan. We're slowly working our way towards the middle, where there's a program that they can pay for and a program that is efficacious. That's the puzzle we're trying to solve for right now. Dr. Pedro Barata: This has been wonderful and super helpful. Before we wrap it up, is there anything else you would like to share with our listeners? Dr. Kathryn Schmitz: I want to make sure that your audience is aware that there are a variety of ways that exercise oncology is practiced. The program that most oncologists will be familiar with is LIVESTRONG, which is a program at the YMCA. It's a free program. At one point, there were over 800 locations across the U.S. They have contracted since COVID, probably because of COVID. So they still do exist but imagine, if you will, telling your patients that chemo is only available Tuesdays and Thursdays at 7:00 p.m. It would be difficult for patients to get there and get the chemotherapy. The same thing is true for the LIVESTRONG program. It's a fantastic, fantastic program for people who are able to get there, but that's one option. Another option for patients is there are a variety of online opportunities. I'll call out 2Unstoppable for women's cancers. It's literally the number 2Unstoppable.org. It's a free program available to women with cancer to have live, small group training programs. And they're based in Virginia, but they have programs all over the country. And then finally, I just want to overemphasize the app, the Cancer Exercise app. It's literally called Cancer Exercise in the app store. And that is a super duper easy button, very comprehensive, developed by a nurse scientist, Anna Schwartz. And then there are a variety of books. I wrote a book called Moving Through Cancer. There's a new book out [MyExerciseMedicine for Cancer] by Dr. Rob Newton as well, who's an Australian author. And there are certifications for exercise professionals that folks can look into as well through the American College of Sports Medicine. Dr. Pedro Barata: Dr. Schmitz, this is fantastic. Thank you for sharing those great insights with us. Super, super helpful. Thank you for taking the time. Dr. Kathryn Schmitz: Thank you so much. Dr. Pedro Barata: Thank you to our listeners for your time today. Remember, you'll find links to Dr. Schmitz's fantastic Educational Book as well as the JCO articles in the transcript of this episode. I'll invite all of you to go and read. And we'll also include a link to Dr. Schmitz's book titled Moving Through Cancer: An Exercise and Strength Program for the Fight of Your Life, which empowers patients and caregivers in simple five steps.  So with that, please join us again next month on By the Book for more insights on key advances and innovations that are shaping modern oncology. Thank you very much for your attention. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:           Dr. Pedro Barata    @PBarataMD     Dr. Kathryn Schmitz @fitaftercancer Follow ASCO on social media:           @ASCO on X (formerly Twitter)           ASCO on Bluesky          ASCO on Facebook           ASCO on LinkedIn           Disclosures:        Dr. Pedro Barata:    Stock and Other Ownership Interests: Luminate Medical    Honoraria: UroToday    Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon    Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas    Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck     Dr. Kathryn Schmitz: Patents, Royalties, Other Intellectual Property: Fees from the educational program developed by Dr. Schmitz that is now offered through Klose Training and Consulting.

Adam Haman returns, this time to discuss a recent paper summarizing the performance of leading LLMs in wargames.Mentioned in the Episode and Other Links of Interest:The YouTube version of this conversation.The NewScientist article reporting (inaccurately) on this research paper.BMS ep 467 on the weaknesses of modern game theory.This episode's sponsors, the Scott Horton Academy and The Swan Brothers.The HamanNature substack.Help support the Bob Murphy Show.

Bob continues his commentary on John chapter 3, this time on verses 13 through 17. This includes the famous verse John 3:16, which lays out the recipe for eternal life through belief in Jesus.Mentioned in the Episode and Other Links of Interest:The previous episode in this series, i.e. BMS ep 475, Installment 10: Being Born Again.John Piper on Moses lifting up the serpent.John Piper answers: Does God love the non-elect? Help support the Bob Murphy Show.

Chapter 129This week Queen tells us about her going to a party with her Dom and we see videos of their BDSM session during the party. Then we discuss all that is going on wit porn and these platforms. Now it's time to podcast and we start with us reacting to two videos from Conversations Tonight. The first one was a lady who had two brain surgeries and she is complaining about her husband not being romantic after he nursed her back to good health. The 2nd one was a lady asking about getting out of and over a lesbian relationship. We unpack both and we discuss the three types of cheater for both men and women. Then , we discuss a lady who has both of her BMs names tatted on her but the real tea is her "I'm His Cum Bucket " Tattoo. Then we unpack bad roommates and more.Watch the Full Episode as a Premium Smoker in The Premium Smoke Room On Loyalfanshttps://tinylf.com/qEOiWRZkp4GCyU9

Live Work with Madeleine I'm Helpless! Part 2 of 3 Today, we are pleased to present the exciting conclusion of our work with Madeleine, a loving mother who fears that her eldest daughter might be in mortal danger during her year abroad. Last week, you heard about the T = Testing and E = Empathy phase of the live work with Madeleine, a mother feeling intense panic and helplessness and inadequacy because she fears that her daughter could be in grave danger of abduction and worse. This week, we will focus on A = Paradoxical Agenda Setting, using the Miracle Cure Question, Magic Button, Positive Reframing, and Magic Dial to see if we can melt away her resistance to change. You can see the Emotions table of the Daily Mood Log Madeleine during the Magic Dial portion of the session if you Click Here As you can see, she wanted to reduce her negative feelings somewhat, but thought she still wanted to keep them fairly elevated, since she still sensed that her daughter might be in real danger, and clearly did not want to abandon her. This is one of the significant refinements in TEAM CBT. First, we want to bring the patient's resistance to full conscious awareness. Second, we want patients to full grasp that their negative thoughts and feelings do NOT result from some "defect" or "mental disorder," but rather from what is most beautiful and awesome about them as human beings. After the Magic Button, David and Jill went on to the final, M = Methods portion of the TEAM session, using tools such as Identify and Explain the Distortions, the Double Standard Technique, and the Externalization of Voices, with the Acceptance Paradox, the Self-Defense Paradigm, and the CAT (Counter-Attack Technique). We will, of course, do numerous role reversals to see if we can get Madeleine to a "huge" victory over her many distorted thoughts. You can see the Daily Mood Log Madeleine prepared at the end of the session if you Click Here As you can see, the reductions in negative feelings were dramatic, but in several areas (anxiety, inadequacy, frustration and anger), Madeleine's negative feelings were still minimally elevated. That is one of the reasons we decided to schedule an additional session together several weeks later to see if we could intensify Madeleine's responses to her negative thoughts, and hopefully due some Cognitive Flooding to complete her "treatment." At the end of these show notes, you will find an email from Madeleine after the session that includes her end-of-session scores on the BMS and EOTS. You will also see comments submitted by many participants who attended the webinar live. This email below from Madeleine following the session shows her end of session scores on the Brief Mood Survey as well as the Evaluation of Therapy Session at the end of her session with Jill and David. Hi David, Yes, here are my BMS & ETS score totals after the extended session. Please let me know if you have any questions. A relapse prevention session would be nice; however, I hesitate to accept your offer as you all are so busy. Please know that I am practicing the PTs and keeping the NTs in check for now. Thank you again a million times over

Bob covers John 3: 1-12, where Jesus tells Nicodemus that he must be born again to see the kingdom of God.Mentioned in the Episode and Other Links of Interest:The previous episode in this series, i.e. BMS ep. 396, Installment 9: Cleansing the Temple.Help support the Bob Murphy Show.

Live Work with Madeleine I'm Helpless! Part 1 of 3 Today, we are pleased to present one of our favorite podcast topics—live work with a real human being who is suffering. We will be working with Madeleine, a woman who read a disturbing article while at the hairdresser and freaked out, sensing that one of her daughters might be in mortal danger. This live and unedited session was first presented as part of a free webinar on September 11, 2025. There was no preparation or role-playing—everything was absolutely real and spontaneous, exactly as it evolved in real time. We present Part 1 as our final Feeling Good Podcast for our 2025 season. This is our most powerful and popular type of podcast, and we hope you enjoy it. We also give a big thanks to our courageous "patient," Madeleine. My co-therapist will be Dr. Jill Levitt, a clinical psychologist and Director of Training at the Feeling Good Institute in Mountain View, California. Jill and I greatly enjoy working together as co-therapists when we teach and we typically see our "patient" for an extended, two-hour session. We find that this is the most effective format for teaching, and that way, we can frequently complete a course of therapy in a single session. However, you do not need more than one therapist to do effective TEAM CBT, and you can do it in conventional 50 minute sessions as well. But often, you can do vastly more in a double session. We will not be engaged in an ongoing therapeutic relationship with Madeleine. When we work with therapists, they are doing personal work as a part of their training. We feel that this experience is vital for every therapist who hopes to do world-class TEAM CBT with their own patients / clients. More than 2,000 individuals registered for this workshop. Although the workshop was open to everyone, only 13% of the participants identified as general public, while 87% identified as mental health professionals.  In Part 1, which we present today, we focused on T = Testing and E = Empathy phases of the TEAM session. In Part 2, which you will hear next week, we will focus on A = Paradoxical Agenda Setting and M = Methods. We will also show you the changes in her scores on the Daily Mood Log (DML) and Brief Mood Survey (BMS) from the start to the end of the session, as well as Madeleine's scores on the Evaluation of Therapy Session (EOTS) at the end, including what she liked the most and least about the session. That way, we can see clearly how much improvement there was (or wasn't) during the session, and how Jill and I did in terms of empathy, helpfulness, and other scales that evaluate the patient's view of the session. In Part 3, which you will hear in two weeks, we did more Externalization of Voices along with Cognitive Exposure, since we had some loose ends we wanted to tie up before completing our work with Madeleine. This follow-up session occurred many weeks after the initial session at the workshop, and will also serve as a follow-up to see how Madeleine did in the days following the live work. Part 1 of 3 Our "patient," Madeleine, is a courageous woman who experienced sheer panic after being triggered at the hair salon while reading an article about a young woman who was abducted. Since Madeleine's oldest daughter's is away at college, taking a year abroad, Madeleine realized she could not protect her from predators and freaked out, thinking about all the horrible things that could happen to her. In addition, Madeleine had many self-critical thoughts about ways she thought she had failed her daughter when her daughter was growing up, and worried about her daughter's judgement: She hasn't always made the best decisions about guys she's gone out with, and she's shared everything with me. She says, 'Don't worry mom. I've learned from this.'" At the start of the session, we reviewed Madeleine's scores on the Brief Mood Survey (BMS). This indicated only minimal depression (5/20), with no suicidal urges or anger, but her anxiety was still extremely elevated (18/20). In addition, her Positive Feelings score was only 20 out of 40, with 0 meaning no positive feelings at all, and 40 being the highest possible feelings. However, her Relationship Satisfaction score with her husband was 25 out of 30, which indicates strong satisfaction, with just a little room for improvement. We will ask Madeleine to complete the BMS again, along with the EOTS, so we can see precisely what changed, and by how much, during the session. Our goal, of course, with TEAM CBT, is nearly always to cause a near-complete, or complete, elimination of symptoms during a single, extended therapy session. In addition, we want every patient to have a crystal clear understanding of how and why they got upset, along with how to use the tools that were the most helpful to them in the session. That way, they'll be armed to deal with future relapses, which are inevitable for all human beings. And here's the big point. Our goal in sharing this session with you is so you can feel inspired, and see that rapid recovery really IS possible. And if you're a therapist, we hope that you will feel motivated to learn TEAM CBT so you can significantly improve your outcomes with your own patients. You can see the Daily Mood Log Madeleine prepared just prior to the session if you Click Here The upsetting situation was reading the article about the young abducted woman in the hair salon. On the Emotions table  she indicated that she was feeling sad, down, and unhappy (85%), anxious, frightened and panicky (100%), inadequate (100%), frustrated (90%), and angry and upset (100%). These extremely high ratings tells us that Madeleine's negative feelings were about as intense as a human being can experience. Although your life is undoubtedly very different from Madeleine's, perhaps you, too, have felt panic and helplessness when you thought the life of a loved one might be in danger. Madeleine generated several additional negative Thoughts during the empathy phase of the session, including, I'm totally responsible for how she's turned out. 95% I was not present enough for her. 95% She may not trust that I'm there for her. 60% She's anxious and insecure and a people-pleasure, and she's also perfectionistic, and it's all my fault. 75% I should have been more sensitive when she was growing up. I expected too much. 100% Again, if you're a parent, you may have had similar negative thoughts about your own parenting. I know that I have! During the Empathy phase, Madeleine described her horrors when reading the article at the hairdresser's, with thoughts of Natalie Hollaway's brutal murder as well as other women who were abducted and murdered. Madeleine explained that she and her husband both married late, and felt somewhat insecure as parents: "It wasn't easy having children late in life. . . .  When our first baby was born, the milk was not coming down. My daughter would look deep into my eyes, and I had the thought, 'I'm letting my daughter down.'" She said she had a rough time when she was growing up and her parents got divorced: "My heart was broken, and I had to learn to be strong. I had to learn not to let so much emotion through. I had to learn how to keep guys at arm's length. I had to protect myself from getting hurt." She said that wanted her daughters to grow up being strong and independent, but as she reflects back, she thinks she may have failed them and not provided enough warmth and support. Our goal during E = Empathy is not to help or even try change anything, but simply to go with our patients to the gates of hell, so they can vent, cry, and express their deepest and most private feelings. At the end of the Empathy portion of the session, we asked Madeleine to grade us on the three key elements of empathy, using letter grades: How accurately did we understand how you were thinking? How accurately did we understand how you were feeling inside? To what extent did we convey the spirit of trust, warmth, and acceptance? She gave us 3 A's, indicating it was time to move on to A = Paradoxical Agenda Setting, which you will hear next week. We will want to find out what Madeleine might want help with. We will also try to melt away her resistance to change using the Miracle Cure Question, the Magic Button, Positive Reframing, and the Magic Dial.    Why would we anticipate resistance? After all, Madeleine is asking for help. But remember, the desire for change cannot always be take for granted in anyone. Nearly all of us have mixed feelings about change. After all, a loving and concerned mother might NOT want to stop worrying about a beloved daughter who seems to be in grave danger! But if you deal with this resistance in a compassionate way, you may open the door to the possibility of rapid healing when you come to the M = Methods portion of the session. We can check it out at the exciting conclusion of the work with Madeleine next week!

Economist Steve Landsburg gives a presentation based on his new book, which uses intuitive analogies to really explain the slowdown in time and other odd implications of the theory of special relativity.Mentioned in the Episode and Other Links of Interest:The YouTube version of this interview.Order Steve Landsburg's books.A great "Mechanical Universe" episode showing Lorentz transformations with intuitive animations.BMS interview with Landsburg on the math genius Grothendieck.Help support the Bob Murphy Show.

Keith Smith is founder of the Surgery Center of Oklahoma. He returns to the podcast to summarize his recent testimony on medical costs.Mentioned in the Episode and Other Links of Interest:The YouTube version of this interview.The CSPAN video of the testimony.The Surgery Center of Oklahoma. The Free Market Medical Association (FMMA). Matt Ohrt's appearance on the BMS.The Tuttle Twins Academy (with Black Friday discount).Help support the Bob Murphy Show.